{
  "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
  "chunks": [
    {
      "text": "(N leit emp häm un NS tlin pfeh mato ng SC nie hun olog gen CLC e nge gisc nkarzi C) and in gesnko no sell olog om lsch gisc m, nich haft zur Dia cher Erht- Agno kun -k ost nge kleinzelligtik und Therapie en",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "",
        "start_page": 1,
        "end_page": 1,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "DGHO Deutsche Gesellschaft für Hämatolo Medizinische Onkologie e.V. Bauhofstr. 12 10117 Berlin Managing Chairman: Prof. Dr. Phone: +49 (0)30 27 87 60 89 - 0 info@dgho.de",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "Publisher",
        "start_page": 2,
        "end_page": 2,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Prof. Dr. med. Bernhard Wörmann Medical Director",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "Contact",
        "start_page": 2,
        "end_page": 2,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The recommendations of the DGHO for the diagnosing of diseases do not relieve the need for diagnosis, individual indication to check! The DGHO überni ogie und . med. Andreas Hochhaus nostik und Therapie haematological wortlicher Ärztin / den verantwortlichen Ärztin / den verantwortlichen, Kontraindikations und Doimmt für Ansprechen keine Gewähe and onkolo- Ärztinosierungen im ehr.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "Source",
        "start_page": 2,
        "end_page": 2,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "2 Grun",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "1 Zusa",
        "start_page": 3,
        "end_page": 3,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "2.2 Epide 2.3 Path 2.4 Risik 3 Vorb",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "2.1 Defin",
        "start_page": 3,
        "end_page": 3,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "3.2 Early 4 Klini 5 Diag 5.2 Diag",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "3.1.Proposal for a Council Regulation (EEC) on the common organization of the market in fruit and vegetables",
        "start_page": 3,
        "end_page": 3,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "5.3 Class",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "5.2.1 First",
        "start_page": 3,
        "end_page": 3,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "5.3.2 Histo 5.3.3 Immm",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "5.3.1.3 Stad",
        "start_page": 3,
        "end_page": 3,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "5.3.3.2 Stad 5.6 General",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "5.3.3.1 Opera",
        "start_page": 3,
        "end_page": 3,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "5.6.2 Geria 5.6.3 Ernä 6 Ther",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "5.6.1 Klinis",
        "start_page": 3,
        "end_page": 3,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "I ammenfassung... nition and basic information emiology... hogenese... cofactors... bending and early detection... recognition... isches Bild... gnosis... gnostics... diagnostics... sification... ern... M and IASLC / UICC8... M and IASLC / UICC9... dium IIIA N2 according to Robinson... ologie... munhistochemistry and geneticly rable stages... dium IV... dium IB... dium IIA and IIB... adjuvant systemic the uvant systemic therapy...",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.4.1.1 Neoa",
        "start_page": 3,
        "end_page": 3,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": ". . . 6.2...3.3.3.11 Afat 6.2 Afat 6.2 Aft 6.2 Af 6.2 Af 6.2 Af 6.2 Nint 6.2 Af 6.3.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "dium IIIA T3 N1, T4 N0, T4 N1",
        "start_page": 3,
        "end_page": 6,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "15 Ans 16 Open Adrenal Metastasis - Associated Lung Carcinoma Habilitation... ht-curatively intended Thera e nature ... erapieprotokolle ... udieprotokolle ... . . .",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "14 Link",
        "start_page": 6,
        "end_page": 6,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "ICD-10: C34.-",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "Lung carcinoma, non-small cell (NSCLC)",
        "start_page": 7,
        "end_page": 7,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Regulations Conflicts of interest Guidelines Report Authors: Frank Griesinger, Gudrun Absenger, Annalen Bleckmann, Wilfried Eberhardt, Martin Eichhorn, Nikolaj Frost, Martin Früh, Oliver Gautschi, Sylvia Gütz, Wolfgang Hilbe, Hans Hoffmann, Rudolf Maria Huber, Klaus Kraywinkel, Sonja Loges, Christoph Pöttgen, Martin Reck, Niels Reinmuth, Martin Sebastian, Jan Michael Siehl, Cornelius Waller, Jürgen Wolf, Bernhard Wörmann In cooperation with the AIO Previous Authors: Robert Pirker, Ron Pritzkuleit, Jan Stöhlmacher, Michael Thomas, Dieter Ukena, Martin Wolf In cooperation with the AIO",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "Preparation of the guideline:",
        "start_page": 7,
        "end_page": 7,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In addition to the disease-related disease-related disease-related disease-",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "1 Executive summary",
        "start_page": 7,
        "end_page": 7,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Lung carcinomas are primarily epithelial malignancies created in the lungs. In therapy-oriented guidelines are further differentiated between small and non-small cell carcinomas, in the non-small cell carcinomas according to histological, genetic and immunohistochemical parameters. The lung is a pre-disposition site for metastases of numerous malignancies. These, further pulmo- nal tumors and benign spatial demands must be anaemic and possibly also pathohisto- logically excluded. The following statements on epidemiology, risk factors, prevention and early detection refer to all forms of lung carcinomas. The subject of the further sections of this guideline are the primary, non-small cell lung carcinomas (non-small cell Lung Cancer, NSCLC).",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "2.1 Definition and basic information",
        "start_page": 8,
        "end_page": 8,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The following results are based on the data of the cancer registers from the individual German federal states, which are merged for nationwide evaluations at the Centre for Cancer Registry Data [111]. In the period 2020 – 2022 NSCLC accounted for about 78% of all lung cancer cases reported to the cancer registers via clinical, praxes or pathologies. 15 % were SCLC, in about 8% of cases no allocation was possible due to non-specific data on histology (\"evil tumor\"). Adenocarcinomas are the largest group within the NSCLC with 55 %,",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "2.2 Epidemiology",
        "start_page": 8,
        "end_page": 8,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "as well as adenosquamosen and large cell/undifferentiated carcinomas (both 1%). Approximately 8% of the cases were encoded as carcinomas or non-small cell carcinomas.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "followed by squamous cell carcinomas (27%). Carcinoids/neuroendocrines Carcinomas (6%)",
        "start_page": 8,
        "end_page": 8,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "33% vs. 20%, inversely, squamous cell carcinomas represent a higher proportion.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "The proportion of adenocarcinomas was higher in women with 62% than in men with 50%, and",
        "start_page": 8,
        "end_page": 8,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "As the approximately 11% of new lung cancers (DCOs) are only known via death certificates in the register, they usually do not allow histological differentiation and therefore enter the incidence of lung cancer, but not in that of the two subgroups, these figures should be considered as minimum figures.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "About 16,500 women and 24,400 men have recently been ill for the first time each year in Germany.",
        "start_page": 8,
        "end_page": 8,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The age-specific rates of disease in men in all Member States are similar to those in the United Kingdom.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "Dian was most recently 69 years old, only about 2% of those affected fell ill before the 50th anniversary of the death.",
        "start_page": 8,
        "end_page": 8,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In the case of pre-stage II cancer, the prevalence of pre-stage III cancer is similar to that of pre-stage III cancer, whereas in the case of pre-stage III cancer, the prevalence of pre-stage III cancer is similar to that of pre-stage III cancer. Since around 2015, the absolute incidence of pre-stage III cancer has been almost constant with a total of around 41,000 diseases per year, following a continuous increase in the years before. Figure 1: Annual incidence rates of NSCLC per 100,000 persons, by age and gender (Germany, 2020-2022) In 52% of new diseases with sufficient documentation of tumour stages, for first diagnosis of NSCLC, only 26% of cases are diagnosed in early stages I or II according to UICC. In the case of squamous cell cancer, distribution is somewhat more favourable than in the case of adenocarcinomas, see Figure 2.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "Age groups and younger women, and women over 60 years of age are still increasing.",
        "start_page": 8,
        "end_page": 10,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Figure 3: Relative survival* up to 10 years after initial diagnosis of an NSCLC, period analysis Legend: *relative to the survival probabilities in the general population with the same age and sex distribution In Austria, lung cancer is second in terms of the absolute number of new cancers, in women and men after breast and prostate cancer.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "The rate of increase in women was higher than in men, at 31.8% vs. 23.3%.",
        "start_page": 10,
        "end_page": 10,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The incidence of cancer is continuing to decline in men, while in women, the incidence of cancer is still decreasing.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "approximately 4,800 people (2,800 men and 2,000 women) for the first time with the diagnosis of lung cancer.",
        "start_page": 10,
        "end_page": 10,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In Switzerland, lung cancer is the second most common cancer in men and women. Half of the cases are diagnosed before the age of 71. The number of deaths in men is the most common and in women the second most common cancer cause. Smoking is the main risk factor for lung cancer.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "stable [88, 89].",
        "start_page": 10,
        "end_page": 10,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "in the last two periods 2012–2016 and 2017–2021. In 2023, foreign people had a 13% higher death rate than Swiss people in lung cancer [15].",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "In the last 30 years (-32% respectively -48 % since 1992),",
        "start_page": 10,
        "end_page": 10,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Lung carcinomas are produced in a complex, step-by-step process through the accumulation of modified molecules and the deregulation of signal transmission pathways on the basis of genetic aberrations. Lung carcinoma is one of the malignancies with the highest mutation load, although this does not apply to all molecular subgroups. Molecular analyses increasingly lead to a diversification of the so far histologically shaped subdivisions. They show different pathogenetic pathways, e.g. between smokers and non-smokers, but also within the histological subgroups. For some of the central oncogeneous Trei- bermutations, targeted drugs are available.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "2.3 Pathogenesis",
        "start_page": 10,
        "end_page": 10,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The interaction with the immune system is also relevant for the spread of the tumour cells.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "2.3 Pathogenesis",
        "start_page": 10,
        "end_page": 10,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "The risk of developing a lung carcinoma is increased by the following factors: acquired, exogenous smoking, also passive smoking inhalation of vapours (vaping) from electronic cigarettes containing liquids containing chemical carcinogens such as acetaldehyde and formaldehyde ionizing radiation (high environmental radon exposure, uranium mining, medical radiation exposure) fine dust diesel exhausts asbestos quartz dust chronic infections genetically, endogenous persons with a positive lung cancer history at one or more applied first degree have an increased risk of disease. Overall, smoking, in particular in active form but also as passive smoking, is by far the most important risk factor.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "2.4 Risk factors",
        "start_page": 11,
        "end_page": 11,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "These include all forms of inhaled tobacco consumption, including water whistles (shisha). The interaction of smoking with other exogenous or endogenous risk factors has not been conclusively clarified, with reference to a overadditive effect, e.g. in case of asbestos exposure. As an occupational disease, lung cancer is a basis by arsenosis, asbestos, bethium bethrium bethrium bethrium.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "2.4 Risk factors",
        "start_page": 11,
        "end_page": 11,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "The general recommendations for prevention refer to the previously identified risk factors and the private lifestyle: non-smoking as the most important measure passive smoking and e-cigarettes avoid occupational exposure to risk substances structural measures to reduce radon exposure in risk areas increased physical activity consumption of fruit and vegetables Avoiding smoking is the crucial prevention measure (WHO Framework Convention on Tobacco Control) [117, 142]. Increased consumption of fruit and vegetables reduces the risk of lung cancer, especially among smokers. Randomized studies in lung cancer risk persons do not have a positive preventive effect for the intake of β-carotene, various forms of retinoids, vitamin E, folic acid, tea extracts, selenium, N-acetylcysteine, acetylsalicylic acid, metformin, celecoxib, inhaled steroids and other substances [135]. Specific forms of food supplementation or medicines for the prevention of lung carcinoma are not recommended.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "3.1 Prevention",
        "start_page": 11,
        "end_page": 12,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "As the diagnosis of a lung carcinoma is confirmed by a diagnosis of the disease in the early stages of the disease, this diagnosis of the disease in the early stages of the disease has been significantly reduced by the diagnosis of the disease in the early stages of the disease. In the case of the disease in the early stages of the disease, the diagnosis of the disease in the early stages of the disease is confirmed by the diagnosis of the disease. In the case of the disease in the early stages of the disease, the diagnosis of the disease in the early stages of the disease is confirmed by the diagnosis of the disease in the early stages of the disease. In the case of the disease in the early stages of the disease, the diagnosis of the disease in the early stages of the disease is confirmed by the diagnosis of the disease in the early stages of the disease.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "3.2 Early detection",
        "start_page": 12,
        "end_page": 12,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "(DRG), the German Society for Pneumology and Respiratory Medicine (DGP) and the German Society for Thoracic Surgery (DGT) Key points for the implementation of a national organized programme in Germany for the early detection of lung cancer in risk populations by means of low-dose CT [11]. In recent years, the conditions for a national early detection programme have been established in Germany. With the entry into force of the BMUV legal regulation on 1 July 2024, early lung cancer detection for risk persons by means of low-dose CT examination in Germany is in principle permitted – under the conditions set out in the legal regulation. The exact implementation provisions and in particular the conditions of reimbursement are currently laid down by the G-BA.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "[109]. In a common position paper, the German X-rays",
        "start_page": 12,
        "end_page": 12,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The combination with an offer for smoking cessation is planned. The start is planned for 2025. A similar programme is currently being evaluated by the Swiss Federal Office for Health Care.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "[109]. In a common position paper, the German X-rays",
        "start_page": 12,
        "end_page": 12,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "Characteristic symptoms are summarized in Table 1. In early lung cancer often asymptomatic. Symptoms such as pain are often external stages. Table 1: Symptoms in patients with lung cancer",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "4 Clinical picture",
        "start_page": 13,
        "end_page": 13,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Locally tumor-related cough dyspnoea thorax pain haemoptysen blood-tungated sputum in coughing upper congestive disease (Vena-cava-superior syndrome) dysphagia stridor hoarseness (voice band paresis in the case of infiltration of the N. recurrens) arm weakness (infiltration of plexus brachialis) horner syndrome (infiltration of the ganglion stellatum) metastasis-related pain, e.g. bone or headache dizziness, headache, neurological failure, confusion, seizures lymph node swelling (supraclavicular) iterus general weight loss weakness fever night sweat paraneoplastic syndromes* autoimmune (collagenosis) endocrin hematologically including clotting cutane, e.g. dermatomyositis metabolic, e.g.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "Cause Symptom",
        "start_page": 13,
        "end_page": 13,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "SIADH (swartz-bartter syndrome) with hyponatriemia.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "Cause Symptom",
        "start_page": 13,
        "end_page": 13,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "The first step is to confirm the clinical or imaging Verdac Table 2. en S usdruc e om) ellig (S just chtsd stage is the ck forward- SCLC), and to the thoraxdia diagnosis, see",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "5.2.1 Initial diagnosis",
        "start_page": 13,
        "end_page": 13,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Laboratory blood count, electrolytes, renal parameters, liver parameters, LDH, coagulation CT1 thorax / upper abdomen with contrast agent, or FDG-PET-CT2 method of first choice MRI3 thorax / upper abdomen with contrast agent Alternative to CT1, if CT cannot be performed Bronchoscopy with biopsy4 in case of imaging suspicion and accessible space requirement Transthoracic biopsy in case of imaging suspicion and peripheral round heart, without possibility of endoscopic securing of the dia- gnosis Legend: 1 CT – computer tomography; 2 FDG-PET-CT – Positron emission tomography with diagnostic CT, possible in Austria; 3 MRI – magnetic resonance tomography; 4 alternative in case of peripheral spatial demands: brush, needle or a.; after securing and differentiation of a primary lung carcinoma by pathology, the liver is a targeted spread diagnosis (staging) with consideration of clinical symptoms; see Table 3. Metastases may occur in non-small cell disease, as well as in the lung.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "Study Recommendation",
        "start_page": 14,
        "end_page": 14,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "BAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "Investigation Note",
        "start_page": 15,
        "end_page": 15,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Since January 1, 2017, the division of the stages according to IASLC/UICC8 gü This has now been revised. With January 2025, the new classifi comes into force, see Chapter 5. 3. 1. 2.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "5.3.1 Stages",
        "start_page": 15,
        "end_page": 15,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The previous classification UICC7 has been established on the basis of data from almost and formally on 1 January 2017 with the cooperation of IASLC/AJC ten. The current stage classification is based on the TNM and see Tables 4 and 5. ndoscopy astasen ert 0M BUS – endobronchial o noscopy, VAMLA: videoas putertomography; valid, see Chapter 5 ication according to IASLC/t 100.000 Pat. übe CC and UICC in Kra d der UICC8 Criteries followed or assisted /UICC9 in aft getra-",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "5.3.1.1 TNM and IASLC / UICC8",
        "start_page": 15,
        "end_page": 15,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "T1a T1a T1a T1b T1c T2 T2a T2b T3 T4 en) N0 N1 N2 N3 M0 M1a M1b M1c M Stad dien according to IASLC Lung Cancer Staging Project Short description Carcinoma in situ largest diameter ≤3 cm, surrounded by lung tissue or visceral pleura, main bronchus not involved Minimally invasive adenocarcinoma largest diameter ≤1 cm diameter >1 and ≤2 cm largest diameter >2 and ≤3 cm diameter >3 and ≤5 cm or infiltration of the main bronchus, but without direct infiltration of the Karina infiltration of the visceral pleura or tumor-related partial atelectase, or obstructive to the total The TIA2 malignancies of malignancies of malignancies in an extrathoracic organ have been reported in Table 5 (>1). Table 6 underscores Katego T (Tumo N (Lymp M (Meta legend: * light blue 6: Besc t) orie or) phknote astase) e: on the TNM stage Tis T1 T2 T2a T2b T3 T4 en) N0 N1",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "en [136],",
        "start_page": 16,
        "end_page": 18,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "N2a N2b N3 M1 M1a M1b* M1c1 M1c2 are added Änderu M Stadungen dien according to IASLC Lung Cancer Staging Project (current changes light blue Short description Carcinoma in situ largest diameter ≤3 cm, surrounded by lung tissue or visceral pleura, main bronchus not involved Minimally invasive adenocarcinoma largest diameter ≤1 cm diameter >1 and ≤2 cm largest diameter >2 and ≤3 cm diameter >3 and ≤5 cm or infiltration of the main bronchus regardless of the distance from the carina, but without direct invasion of the Karina infiltration of the visceral pleura or tumor-related partial atelectase or obstructive pneumonia, which up to the hilus rei- and parts of the lung or the entire lung include major diameter >3 and ≤4 cm diameter >4 and ≤5 cm largest diameter >5 but greater than 7 cm of the total or intrafluta. 1 TB2 TB2 TB2 TB2 TB2 T2 TB2 T2 T2 T2 The classification according to Robinson is partly taken over in the new UICC9 classification.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "N2*",
        "start_page": 18,
        "end_page": 20,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The classification according to Robinson now refers to the UICC stages IIIA and B Table 8: Subclassification of the stages T3 / T4 N2 according to Robinson [114]",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "N2*",
        "start_page": 18,
        "end_page": 20,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "In the case of an incidental lymph node metastases, in the case of an incidental lymph node (intraoperati- ver fast-section) or in the case of an incidental lymph node (intraoperati- ver Schnellverschnitt), in the case of an incidental lymph node (intraoperati- ver Schnellverschnitt) or in the case of an incidental lymph node (intraoperati- ver Schnellverschnittung), in the case of an incidental lymph node (intraoperati- verschnittung) or in the case of an incidental lymph node (intraoperati- verschnittung) in the case of an incitational lymph node (intraoperati- verschnittung).",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "Stage Description",
        "start_page": 20,
        "end_page": 20,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The current histological classification according to WHO / IARC is summarised in Table 9. Table 9: Histological classification of NSCLC according to WHO / IARC",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "5.3.2 Histology",
        "start_page": 20,
        "end_page": 20,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "squamous cell carcinoma Horned non-horned (p40+, TTF1) (p40+, TTF1) Basaloid p40+/TTF1 adenocarcinoma Preinvasive <3cm with <5mm invasion minimal invasively invasive G1 lepidic G2 azinary, papillar G3 micropapillary, solid variants",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "Classification Differentiation Characterisation/criteria",
        "start_page": 20,
        "end_page": 20,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Neuroendocrine tumors Carcinoid typical carcinoid atypical carcinoid small cell carcinoid (SCLC) large cell neuroendocrine carcinoma (LCNEC) The neuroendocrine tumors (NET) of the lungs are particularly relevant. Their spectrum is wide and ranges from the relatively indolent carcinoids to the aggressive small cell lung carcinoma (SCLC). The latter are treated in the Onkopedia guideline lung carcinoma, small cell (SCLC).",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "Large cell carcinoma",
        "start_page": 20,
        "end_page": 21,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Diagnostics should include all parameters that are predictive for pre- and post-operative, systemic therapy. In addition, early, comprehensive diagnostics can help to initiate the optimal therapy quickly in case of recurrence or refractoryness.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "5.3.3 Immunohistochemistry and genetic alterations",
        "start_page": 21,
        "end_page": 21,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Testing for markers that are controlling for perioperative systemic therapy is required. These include: PD-L1 Expression to Tumor Cells ALK Translocations",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "5.3.3.1 Operable Stadiums",
        "start_page": 21,
        "end_page": 21,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "A comprehensive molecular testing is discussed as in stage IV. Background to this extended recommendation is the rapidly growing evidence base, whether and which patients with driver mutations such as ROS1, RET and others benefit from perioperative immuno-, immuno-chemo- or target- ted therapy.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "EGFR mutations del19 and L858R",
        "start_page": 21,
        "end_page": 21,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The diagnosis of therapy-relevant alterations should be carried out with all patients in stage IV prior to the start of an exogenetic first-line therapy. It should record these aberrations (in alphabetical order). ALK Translocations BRAF V600E Mutation EGFR Exon 18-21 Mutations HER2 Mutations KRAS G12C Mutation c-MET Exon 14 Skipping Mutations NTRK Translocations RET Translocations ROS1 Translocations The diagnosis should be carried out on the tissue. If there is not enough material or the biopsy of an informative lesion due to the puncture risk is not acceptable, the execution of a liquid biopsy is recommended.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "5.3.3.2 Stage IV",
        "start_page": 21,
        "end_page": 22,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The early detection can be relevant for a necessary change of therapy in chemo- or immuno-therapy-inconsequentiality or in case of rapid progression, if applicable, a more comprehensive diagnosis should be carried out for the diagnosis.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "5.3.3.2 Stage IV",
        "start_page": 21,
        "end_page": 22,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "The treatment options for patients with lung cancer are often restricted by reduced general status as well as cardiovascular, pulmonary or other, also age-related comorbidities. This concerns both curative and palliative therapy. The individual general condition is usually indicated in oncology with the ECOG Performance Score (PS), which is also used in the selection of patients for clinical trials. Here, patients with ECOG PS above 2 are generally excluded, therefore there is little evidence for oncological treatments for such populations, see also Chapter 5. 6. 2.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "5.6 General state and comorbidity",
        "start_page": 22,
        "end_page": 22,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In the absence of primary contraindications against surgery, the expected postoperative lung function (see Table 10) and perioperative cardiovascular risk should be taken into account (see Table 11). A differentiated algorithm for the pre-therapeutic fitness of Pat. with lung carcinoma was developed by the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS) [14, 117]. Table 10: Studies on lung function [14, 117]",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "5.6.1 Clinical and functional operability",
        "start_page": 22,
        "end_page": 22,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Spirometry: FEV11, TLCO2 Methods of first choice Whole-body plethysmography Arterial blood gases at rest Spiroergometry at Pat. with restriction of FEV1 and / or diffusion capacity (TLCO), or other limiting cardiovascular risks or concomitant diseases Legend: 1 FEV1 – forced expiratory 1-second volume; 2 TLCO – CO transfer factor (CO diffusion capacity), formerly and in the USA also referred to as DLCO; Table 11: Clinical predictors of an increased, perioperative, cardiovascular risk (according to American College of Cardiology (ACC) and American Heart Association (AHA)) [66]",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "Investigation Note",
        "start_page": 22,
        "end_page": 23,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "highly unstable coronary heart disease of recent myocardial infarction with evidence of relevant risk of ischemia, based on clinical symptoms or non-invasive examinations of unstable or severe angina (Grade 3 or 4) decompensated heart failure significant arrhythmias AV Block II. or III. Grade symptomatic ventricular arrhythmias in heart failure supraventricular arrhythmias with non-controlled heart rate severe heart valve disease moderate mild angina pectoris (Grade 1 or 2) preceding myocardial infarction, based on history or pathological Q zacken compensated heart failure or Z. decompensated heart failure diabetes mellitus low-advanced age (>70 years) abnormal ECG (left ventricular hypertrophy, left-handling block, ventricular changes in the absence of sinus rhythm in normal frequency chamber action (e.g.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "Risk parameter",
        "start_page": 23,
        "end_page": 23,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "atrial fibrillation) low resilience Z.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "Risk parameter",
        "start_page": 23,
        "end_page": 23,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "The use of Geriatric Assessment instruments is recommended for the objective assessment of the general condition, see the Geriatric Assessment Knowledge Base. Tests for the objectification of mobility and comorbidity are particularly suitable. The indication for carrying out further tests is based on the clinical impression and the planned treatment.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "5.6.2 Geriatric Assessment",
        "start_page": 23,
        "end_page": 23,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "About 35% (one third) of all patients with lung carcinoma are malnourished [75]. All patients should be offered a screening for malnutrition with a validated tool [63]. In case of risk constellation in screening, further diagnostics and professional nutrition advice should be offered. All patients should be motivated and guided to regular muscle training to support body cell mass.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "5.6.3 Nutritional status",
        "start_page": 23,
        "end_page": 23,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In the case of a pre-examination of the pre-in. The importance of the therapy with pembrolizumab when achieving complete pathological remission (pCR) is currently under discussion. Pat. may benefit in particular with non-PCR from adjuvaten CPI therapy. 12 pembrolizumab is approved in this indication. In the subgroup analysis of the approval study, no significant advantage in relation to disease-free survival compared to the control arm is shown for Pat. with a PD-L1 expression <1%. Data on overall survival have not been published yet.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1 Therapeutic structure",
        "start_page": 23,
        "end_page": 24,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The treatment claim is curative. The surgery is the therapy of choice if no indications are available. The postoperative 5-year survival rates for the Stadi are 80-93% [44, 83, 149]. Adjuvant chemotherapy does not improve the 5-year survival. In the postoperative situation after R0 resection, radiotherapy has a ven influence on the prognosis and is not indicated. Ablative radiation therapy (SABR or SBRT) is a potential alternative as a primary therapy, especially in functionally inoperable Pat. In a cohortverg National Cancer Database of the USA, the stereotactic of conventional frak radiation is superior in terms of overall survival [50]. With stereotactic, local control rates can be achieved, which are comparable to those of surgery two randomized studies (STARS, ROSEL) for comparison of stereotactic Strah ah ah ah a h a h ah a h a h",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.1 Stage IA",
        "start_page": 24,
        "end_page": 25,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The treatment claim is curative. The surgery is the therapy of choice if there are no contraindications. The postoperative 5-year survival rates for stage IB in the now valid stage classification are 73% [44, 83, 149]. The change in the classification of UICC7 to UICC8 has also affected stage IB, tumors >4 cm are now part of the IIA stadium, see Chapter 6. 1. 3. In systemic therapy, this change concerns especially their patients with evidence of one of the EGFR common mutations del19 or L8585R and the option of adjuvant therapy with osimertinib, see Chapter 6. 1. 3. 2, or if an ALK translocation of adjuvant therapy with alectinib, see Chapter 6. 3.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.2 Stage IB",
        "start_page": 25,
        "end_page": 25,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "2. Adjuvant radiation is only indicated after incomplent resection (R1, R2), if post-operative treatment is not possible. In the post-operative situation after resection, it has a negative effect on therapy.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.2 Stage IB",
        "start_page": 25,
        "end_page": 25,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "The treatment claim is curative. The surgery is the decisive treatment modality designed for curation, if no contraindications are available, see Chapter 5. 6. 1. The postoperative 5-year survival rates for stage IIA are between 60 and 65%, for stage IIB between 53 and 56% [44, 83, 149]. In stage IIA and IIB, additionally, a system therapy, neoadjuvant or adjuvant, is to be performed. In most of the studies on immunocheckpoint inhibitor (CPI) mentioned below, patients with EGFR mutation del19 / L858R or ALK translocation were excluded. For this reason, an initial molecular pathological diagnosis in stage II is recommended and, if an EGFR or ALK driver mutation is detected, it is advised to use CPI.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.3 Stage IIA and IIB",
        "start_page": 25,
        "end_page": 25,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The significance of the neoadjuvant regimen was confirmed by the influx of epidemiology in the first half of the second half of the third half of the fourth half of the third half of the fourth half of the second half of the fourth. However, in the course of the study, there was no increase in the number of patients who had been treated with chemotherapy. In the study AEGEAN, the combination of platinum-based chemotherapy with durvalumab with chemotherapy with Pat. in the stages II - IIIB (N2 stage) resulted in an increase in the rate of complete pathological emissions (17.2 vs. 4.3 %, p<0.001) and in the extension of the event-free survival time (HR 0.68; p=0.004) [54].",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.3.1 Neoadjuvant systemic therapy (induction therapy)",
        "start_page": 25,
        "end_page": 26,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In the study, Pat., in which a pneumonectomy was planned for the EU, was excluded from the treatment with placebo. In the course of the study, there was no increase in the number of patients who had been treated with chemotherapy.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.3.1 Neoadjuvant systemic therapy (induction therapy)",
        "start_page": 25,
        "end_page": 26,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "In the case of an EGFR common mutation (del19, L858R), GFR common mutations (del 19, L858R) in the ADAURA study, adjuvant therapy with osimergib for 3 years. In the ADAURA study, adjuvant therapy with an EGFR common mutation (del 19, L858R) was associated with an EGFR common mutation (e.g. IB II, II, II, II, III, III, III, III, II, II, II There was no significant benefit in this patient population for atezolizumab (HR 0.42; p < 0.001) [36, DL-risk and exclusion of atezolizumab]. In this patient population, survival data were significant for atezolizumab (HR 0.42; p < 0.001) [36, DL-risk and exclusion of atezolizumab]. with the driver alterations ROS1, RET and NTRK, the use of CPI in the non-curative situation with high probability does not bring any advantage. Their value in the adjuvant situation is not assured in these patients. For a reliable decision basis, the early molecular pathological testing for the relevant genetic alterations is required in the first diagnosis. If appropriate proof is given, adjuvant immunotherapy may not be indicated. The cost of this testing is currently not assured in Germany. Duration of therapy In the majority of the studies on the neoadjuvant combination of chemotherapy with a CPI, immunotherapy was continued as adjuvant therapy over a limited period of time.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.3.2 Adjuvant systemic therapy",
        "start_page": 26,
        "end_page": 28,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In the postoperative situation after R0 resection, radiotherapy has a negative impact on the prognosis, and is therefore not indicated. Radiotherapy is the standard as a primary therapy measure for definitely inoperable patients. It may also be indicated in an R1 or R2 situation if re-operation is not possible.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.3.3 Adjuvant radiotherapy",
        "start_page": 28,
        "end_page": 28,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Stage III comprises a very heterogeneous group of patients, see Figure 3 and Chapter 5. 3. 1. In principle, there is also a curative claim to treatment here. The 5-year survival rates for stage IIIA range between 15 and 40 %, for stage IIIB (N2) between 15 and 30 %, and for stage IIIC between 5 and 10 % [44, 83, 149]. Above all, the extent and location of lymph node metastases are prognostically relevant. For the lymph node status N2 of stage IIIA-B, subclassification according to Robinson allows therapy in dependence of mediastinal lymph node infestations, see Chapter 5. 3. However, it must be noted critically that the subclassification according to Robinson before the wider use of sensitive and specific imaging procedures such as PET and the use of neoadjuvant chemoi- mmu therapies has been developed.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.4 Stage III – Overview",
        "start_page": 28,
        "end_page": 28,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The treatment recommendations for Pat. in clinical stage T3 N1, T4 N0 and T4 N1 essentially correspond to those for stage IIB, see Chapter 6. 1. 3. A neoadjuvant chemoimmunherapie should be preceded by surgery, see Chapter 6. 1. 3. 1. The surgery is the local therapy of choice if there are no contraindications due to tumor localisation or comorbidities. Neoadjuvant chemoimmunherapie should be preceded by surgery, see Chapter 6. 1. 3. 1. Usually Pat. should be presented with infiltration of thoracic wall (T3), vertebral body, pulmonary artery, mediastinum, trachea or bifurcation (T4 extension (T4 Ext)) to evaluate the potential resectability of an experienced thoracic surgeon in an interdisciplinary tumour board. In the case of infiltration of aorta or oesophage (T4 ext) , the treatment should be treated with more relucantly because of a high rate of lung.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.4.1 Stage IIIA T3 N1, T4 N0, T4 N1",
        "start_page": 28,
        "end_page": 28,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In addition to the data in Chapter 6.1.3., data from the open-label, randomised Phase II study NADIM II are available at 86 Pat. in stages IIIA and IIIB. In NADIM II, the neoad juvant combination of platinum-based chemotherapy and nivolumab vs chemotherapy led to an increase in the rate of complete pathological emissions (37 vs. 7%, p=0.02), to prolong the PFÜ (HR 0.47; CI 0.25-0.88) and the ÜLZ (HR 0.43; CI 0.19-0.98) [104].",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.4.1.1 Neoadjuvant systemic therapy at resectable stage III",
        "start_page": 29,
        "end_page": 29,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In the case of the epidemiology, the incidence of the epidemiology was not increased. In the case of the epidemiology. In the event of an accident, the first phase of the treatment was performed with the TB TDI. In the case of the first phase of the treatment, the first phase of the treatment was performed with the TDI. In the case of the first phase of the treatment, the second phase of the treatment was performed with the TDI. In the case of the first phase of treatment, the first phase of the treatment was performed with the TDI. This is particularly relevant when the T3 criterion is based on the tumor size, breast wall infiltration or a size between 5 -7 cm. In addition, the majority of patients who have been diagnosed with the disease have been treated with the disease.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.4.1.2 Adjuvant systemic therapy at resectable stage III",
        "start_page": 29,
        "end_page": 31,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In addition, the incidence of the disease is confirmed by the incidence of the disease. In the studies Checkmate 816 for monotherapy with nivolumab, KEYNOTE 671 for immunochemotherapy with pembrolizumab, AEGEAN for immunochemotherapy with durvalumab, CheckMate 77T for immunochemotherapy with nivolumab and in NADIM II, Pat. in the stage IIIB (N2 stage) were included. Data for the direct comparison of the definitive radiochemotherapy vs of neoadjuvant immunochemotherapy is not yet followed by surgery. In the case of radiotherapy alone, the incidence rate of the disease was not confirmed. In the study PACIFIC in stage III with non-resectable lung carcinoma (HR 0.51; p<0.001) and the ÜLZ (HR 0.68; p=,0025) [4]. The approval for the EU is limited to Pat.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.4.1.2 Adjuvant systemic therapy at resectable stage III",
        "start_page": 29,
        "end_page": 31,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "with a PD-L1 expression ≥1%, in Switzerland this limitation is not valid, see the Actu-ll valid approval information. In addition, in the case of treatment of the disease, the treatment of the disease should be subject to the general condition and to the size of the therapeutic target volume. In a study in Japan, the combined radiochemotherapy with low-dose carboplatin led to an extension of survival time [7]. However, these data contradict older, clearly negative study results for the use of carboplatin as a radiositizer [8]. In addition, the Japanese study showed a significant haematological toxicity. In the case of treatment of patients with EGFR common mutation (del19, L858R), the consolidating therapy with osimertinib was not considered as a sign of pneumonitis and with a PD-L1 expression ≥1%, see chapter 6.1.4.3. In the case of therapy with EGFR common mutation (del19, L858R) one month of the following therapy with osimertinib was not considered as a condition of survival.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.4.1.2 Adjuvant systemic therapy at resectable stage III",
        "start_page": 29,
        "end_page": 31,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 2
      }
    },
    {
      "text": "A combined definitive radiochemotherapy is recommended, see Chapter 6. 1. 4. 4. It follows with Pat. without disease progress: Durvalumab as consolidation immunotherapy over 1 year in Pat. without signs of pneumonia and with PD-L1 expression ≥1%, in Switzerland regardless of the PD-L1 expression, exceptions are Pat. with ALK translocation as well as driver alterations ROS1, RET and NTRK, in which the effectiveness of therapy with CPI is not assured. Osimertinib with Pat. with EGFR commutation, see Chapter 6. 1. 4. 4. In Pat., which are not to be treated locally curatively, or whose tumors are not irradiated within the framework of nor mal tissue tolerance, therapy is performed in non-curative intention.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.4.5 Stage IIIC",
        "start_page": 32,
        "end_page": 32,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In the case of an induction therapy, the induction therapy should not be performed with an induction therapy. In the case of an induction therapy, the induction therapy should be performed with an induction therapy. The superiority of this option is not supported by data from prospective studies, but is recommended as an expert consensus. Regarding possible use of osimertinib or alectinib in adjuvant therapy, we refer to Chapter 6. 1. 3.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.5 Pancoast tumor",
        "start_page": 32,
        "end_page": 32,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "More than 50% of patients with non-small cell lung cancer are diagnosed in stage IV. In the majority of patients, the claim for therapy is not curative [44, 83, 149]. Except for patients in the newly defined, so-called oligometastatic stage M1b, e.g. with solitary adrenal, CNS or lung metastases, where a potentially curative therapy approach is considered.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.6 Stage IV",
        "start_page": 32,
        "end_page": 33,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The Exposition of an Exposition of the Exposition of Exposition of Exposition of the Exposition of Exposition of Exposition of the Exposition of Exposition of Exposition of the Exposition However, in the course of the multimodal treatment protocol, there is a need for an in-patient-to-patient-to-patient-to-patient-to-patient-to-patient-to-patient-to-patient-to-patient-to-patient-to-patient-to-patient-to-patient-to-patient-to-patient-to-patient-to-patient-to-patient-to-patient-to-patient-to-patient-to-patient-to-patient-to-patient-to-patient-to-patient-to-patient-to-patient-to-patient-to-patient-to-patient-to-patient-to-patient-to-patient-to-patient-to-patient-to-patient-to-patient-to-patient-to-patient-to-patient-to-patient-to-patient-to-patient treatment.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.6.1 Stage IVA with oligometastatic disease",
        "start_page": 33,
        "end_page": 34,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In these patients, the therapeutic goal is not curative [51, 52, 82, 117]. The therapy involves the treatment of physical and psychological complaints. It is interdisciplinary. Diagnosis is symptomatic and therapeutic, see Table 2.Systemic therapy has been performed for Pat. with non-small cell lung cancer for many years only according to clinical criteria such as comorbidity and general condition. The current recommendations are based on predictive histological, immunohistochemical and genetic markers. The algorithm for systemic therapy is shown in Figure 5, Figure 6 and Figure 7. Figure 5: Algorithm for systemic therapy in advanced stages – Overview",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.6.2 Stage IVB with multiple metastases",
        "start_page": 34,
        "end_page": 34,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In addition, it is not possible to use the ALIBTI-TIBTI-TIBTI-TIBTI-TIBTI-TIBTI-TIBTI-TIBTI-TIBTI-TIBTI-TIBTI-TIBTI-TIBTI-TIBTI-TIBTI-TIBTI-TIBTI-TIBTI-TIBTI-TIBTI-TIBTI-TIBTI-TIBTI-TIBTI-TIBTI-TIBTI-TIBTI-TIBTI-TIBTI-TIBTI-TIBTI-TIBTI-TIBTI-TIBTI-TIBTI-TIBTI-TIBTI-TIBTI-TIBTIBTI-TIBTIBTI-TIBTIBTI-TIBTIBTI-TIBTIBTI-TIBTIBTI-TIBTIBTI-TIBTIBTI-TIBTIBTIBTI-TIBTIBTI-TIBTIBTI-TIBTIBTI-TIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTIBTI Generation: gemcitabine, pemetrexed, vinorelbin; pemetrexed only for non-plate cell carcinoma; 8 afatinib only for squamous cell carcinoma; 9 PD-1/PD-L1 inhibitor: atezolizumab (independent of PD-L1 expression), nivolumab (independent of PD-L1 expression), pembrolizumab (only for TPS ≥1%); the efficacy is not demonstrated in patients pre-treated in initial line therapy with an immunocheckpoint inhibitor; the therapeutic indication is based on the general condition, pre-treatment, ptomatics, specific comorbidity and Pat preference. The selection of the substrate is determined by the histological classification of the tumor, genetic aberrate (molecular-stratified therapy) and the degree of PD-L1 expression on the tumor immune cells.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "Figure 6: Algorithm for molecular stratified therapy in advanced stages",
        "start_page": 35,
        "end_page": 36,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The knowledge of the therapeutic options enables an optimal maturation and sym-tran- tion r.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "Figure 6: Algorithm for molecular stratified therapy in advanced stages",
        "start_page": 35,
        "end_page": 36,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "In addition, in the case of BTI, the incidence of BTI, BTI, BTI, BTI, B, B, B, BTI, BTI, B, B, B, B, B, BTI, B, B, B, B, Brigatinib did not lead to a signi- fictitious prolongation of the ÜLZ. However, in the case of BIM, the BIM, the BAM, the BAM, the BAM, and the BIM, the BAM, the BAM, the BAM, and BAM, the BAM, the BAM, the BAM, and BAM, and BAM, the BAM, the BAM, the BAM In the case of ALTemitribin, ALTemitribin, ALTemitribin, ALTemitribin, ALTemitribin, ALTinibin, ALTinibin, ALTinibin, ALTini, ALTini, ALTini, ALTin, ALTini, ALTini, ALTini, ALTin, ALTin, ALTin, A",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.6.2.1.1 ALK Translocation",
        "start_page": 37,
        "end_page": 38,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "BRAF-inhibitor dabrafenib in a single-arm phase II study in combination with the MEK inhibitor Trametinib. BRAF-inhibitor dabrafenib in combination with the MEK-inhibitor Trametinib in combination with the MEK-inhibitor. BRAF-inhibitor dabrafenib in combination with the MEK-inhibitor Trametinib in combination with the BRAF-inhibitor is not treated with the BRAF-inexhibitor.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.6.2.1.2 BRAF mutations",
        "start_page": 38,
        "end_page": 39,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "EGFR mutations are not found in Germany. In the case of EGFR mutations, in the case of EGFR mutation, in the time and in the case of EGFR, in the case of EGFR. In the randomised FLAURA study, osimertinib in the first-line treatment with L858 was significantly more pronounced (HR 0.47) than in the other patients with Osimertin. In the first-line treatment with L858 the difference was significantly greater (HR 0.47) than in the other patients with PFÜ (HR 0.62; p<0.0001) and in the overall survival [87]. In the subgroup of Pat. with L858 the difference was markedly greater (HR 0.47) than in the absence of PFÜ (HR 0.75). This difference may be explained by the decision between osimertinib monotherapy and combination therapy.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.6.2.1.3 EGF mutations",
        "start_page": 39,
        "end_page": 41,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "For the first 4 months of therapy, a drug-related antithrombosis prophylaxis was recommended in the first 4 months of therapy. In the first 4 months of therapy, the anti-thromboem therapy was recommended in the first 4 months of treatment. In the first 4 months of treatment, the anti-thromboem therapy with the anti-throem therapy. The additions of the EGFR2 to the EGFR.FR to the EGFR Osimertinib can therefore be considered an alternative to afatinib, but the data on afatinib is larger including the randomized Phase II study. An adequate preemptive side effect management of cutaneous and gastrointestinal adverse reactions in afatinib is essential.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.6.2.1.3 EGF mutations",
        "start_page": 39,
        "end_page": 41,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "In the EU, \"activating\" mutations are widely covered by the approval of the two TKIs. In the USA and Switzerland, separate approvals for afatinib are available for G719X, L861Q and S768I mutations.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.6.2.1.3 EGF mutations",
        "start_page": 39,
        "end_page": 41,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 2
      }
    },
    {
      "text": "The EGFR4 has been found in the EGFR4 population. The EGFR4 population is found in the EGFR2 population. The EGFR2 population is found in the EGFR2 population. However, in the case of an Exon 20 In the case of a CPI monotherapy [92], the EGFR has not been approved by the EGFR. In the case of an EGFR Exon 20 In the case of an EGFR, the EGFR has not been approved by the EGFR. In the case of an EGFR, the EGFR has not been approved by the EGFR. In the case of an EGFR, the EGFR. In the case of an EGFR. In the EGFR. In Switzerland, afatinib is approved for the treatment of the following rare EGFR mutations: G719X, S768I and L861Q. Due to the rarity, the majority of the individual mutations occurred only once in the researched collective, which is why decision-making in molecular tumor boards should be carried out especially for this group.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.6.2.1.3.4 T790M mutation (UC II)",
        "start_page": 41,
        "end_page": 43,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "HER2 (Human Epidermal Receptor 2) is mutated in 1-4% of NSCLC and overex-pressed in 30%. The first line is based on immunochemotherapy based on retrospective analyses in this subgroup [118]. In Pat. with the detection of a HER2 mutation trastuzumab deruxtecan is approved for second-line therapy. The basis were the data from the Phase II study DESTINY Lung02. Here trastuzumab deruxtecan resulted in a response rate of 49% at the dosage of 5.4 mg/kg bw, a median progression-free survival of 9.9 and a median overall survival time of 19.5 months. [69] Special side effect is an interstitial lung disease, see medicinal product Trastuzumab deruxtecan.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.6.2.1.4 HER2 amplifications and mutations",
        "start_page": 43,
        "end_page": 43,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Oncogene KRAS-Mutations of a 2nd to 2nd to 3nd to 3nd to 2nd to 2nd to 2nd to 3nd to 2nd to 2nd to 3nd to 3nd to 3nd to 4th to 4th to 4th to 4 and 3nd to 4th with 4th with 4 and 3th with 4 with 4th with 4th with 4th with 4 with 4 with 4th with 4th with with 4 with 4 with 4",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.6.2.1.5 CRAS mutations",
        "start_page": 43,
        "end_page": 43,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In the case of TSCLC, however, there are several MET alterations, which can lead to constitutive activation of the anti-diagnosis regimen. In the case of TSCLC, however, there are no anti-diagnosis regimens. In the case of TSCLC, however, there are no anti-diagnosis regimens. In the case of TSCLC, there are no anti-diagnosis regimens with anti-diagnosis regimens. In the case of TSCLC, the anti-diagnosis regimens with anti-diagnosis regimens.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.6.2.1.6 c-MET alterations",
        "start_page": 43,
        "end_page": 44,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Gen fusions involving NTRK genes (NTRK1, NTRK2, NTRK3) have been identified as a very rare subgroup in a variety of malignant tumours, including NSCLC with an incidence of 0.1 to 0.3%. Targeted medicinal products are larotrectinib and entrectinib. In a phase I/II study on larotrectinib, 5 out of 7 patients spoke in Entrectinib 7 out of 10 patients [29]. Remissions are sustainable. Larotrectinib has been approved by the EMA since September 2019, entrectinib since 2020 in NTKR fusion gene positive tumours, if no satisfactory alternative therapy is available. The third NTRK inhibitor was approved for the EU at the beginning of 2025. The basis was Phase I/II study TRIDENT-1. Here, remission rate of 62% was achieved with reprot rectinib in first-line therapy, with pre-treated Pat. [132] chemotherapy was achieved in Pat.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.6.2.1.7 NTRK translocation",
        "start_page": 44,
        "end_page": 44,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "with NTRK tranctions, an option is also unclear.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.6.2.1.7 NTRK translocation",
        "start_page": 44,
        "end_page": 44,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "The RET gene coded a receptor tyrosine kinase that is active in different cells. RET may merge with different genes in the NSCLC. Most common fusion partner is KIF5B, other genes are CCDC6, NCOA, TRIM33, CUX1, KIAA1217, FRMD4A and KIAA1468. Insofar as the specific fusion partner plays a role in the prognosis of the disease and for the effectiveness of the therapy, is currently not conclusively clarified. RET gene relocations are detected in 1-2 % of NSCLC-Pat. They are associated with adenocarcinoma, younger age and non-raiser history. RET gene relocations rarely occur with other driver mutations. Selpercatinib and Pralsetinib have been approved with two highly effective, specific RET inhibitors in advanced NSCLC, see drug approval status.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.6.2.1.8 RET translocation",
        "start_page": 44,
        "end_page": 45,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "nib vs. plat-containing chemotherapy ± pembrolizumab for significant extension of the PFÜ (HR 0.46; p<0.001) [157] and to improve parameters of quality of life. Data on the influence on the ERZ are still immature. Also approved was pralsetinib based on the RET fusion-positive, advanced NSCLC, which had not previously been treated with a RET inhibitor. In the open, international, multicentre phase 1/2 study ARROW, pralsetinib resulted in remission of 72% of patients without prior therapy and 61% of patients previously treated. The median PFÜ was 13-16 months. The overall survival rate after 24 months was 63 and 72% [41]. Pralsetinib was withdrawn from the market by the pharmaceutical entrepreneur in 2023, while the results of a direct comparison of the study on Pralsetinib vs selbercatinib were not available. Some of the multikinase inhibitors approved for other tumours are also effective in the case of the above-referior-resistance-res-receptive-res.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "In the first-line therapy, the study LIBRETTO-431 showed that",
        "start_page": 45,
        "end_page": 45,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "and chemotherapy with platinum and pemetrexed. These include cabozantinib, vandetanib, lenvatinib and sunitinib.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "Your use may occur after failure of pralsetinib or selpercatinib.",
        "start_page": 45,
        "end_page": 45,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The efficacy of pembrolizumab in combination with the RET fusion positive NSCLC [157].",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "The efficacy of CPI has not been established and the LIBRETTO-431 study has not shown any additional efficacy.",
        "start_page": 45,
        "end_page": 45,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In one study of 1 to 2 months, the rate of incidence was similar to that of 1 to 4 months, with 1 to 6 months, with 1 to 7 months, with 1 to 8 months, with 1 to 9 to 9 months, with 1 to 10, with 1 to 9 to 9 months, with 1 to 12 months, with 1 to 10, with 1 to 12, with 1 to 12 months, with 1 to 9 to 6 with 1 to 12, with 1 to 6 with 1 to 12, with 1 to 12 months, with 1 to 12, with 1 to 12 months, with 1 to 12, with 1 to 6 to 12, with 1 to 12, with A new option is approved for Repotrectinib, an inhibitor of ROS1 and of Tropomyosin-receptor-tyrosin kinases. In Phase I/II study TRIDENT-1 for ROS1 fusion-positive Pat.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.6.2.1.9 ROS1 translocation",
        "start_page": 45,
        "end_page": 46,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Repotrectinib in 71 was not previously treated with TKI. 10 out of 17 patients with resistance mutation G2023R also responded to therapy. 8 out of 9 patients with cere-brale metastases responded to therapy with Repotrectinib [33]. After failure of first-line therapy a rebiopsia should be targeted.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.6.2.1.9 ROS1 translocation",
        "start_page": 45,
        "end_page": 46,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "This population comprises 70-80% of all patients with NSCLC in stage IV. The previous predictive significance of histological classification has increasingly been detached from biological parameters. However, histological classification into adenocarcinoma, squamous cell carcinoma or non squamous cell carcinoma is still relevant to therapy if this classification was the basis of approval studies such as pemetrexed or bevacizumab.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.6.2.2 Non-molecular stratified therapy",
        "start_page": 46,
        "end_page": 46,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Standards in the therapy of Pat. without genetic aberrations, for which targeted drugs are approved, are immuno-, immuno-chemo- and chemotherapy. The recommendations are based on PD-L1 status, histology and suitability for platinum-based chemotherapy [47]. The evidence can be summarised as follows:",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.6.2.2.1 First line therapy",
        "start_page": 46,
        "end_page": 46,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In the case of anti-Pharma-tion, the incidence of anti-Pharma-tion has been increased by ≥ 50% compared to platinum-based chemotherapy (HR 0.63; p=0.0070) and a decrease in the rate of severe adverse reactions (52.5 vs 30.1%). In the study EMPOWER-Lung 1, monotherapy with the anti-Pharma-tion Cemi-L1-Plimab has also been reported in patients with a PD-L1-expression ≥50% compared with platinum-based chemotherapy (HR 0.76; AI in the study EMPOWER-Lung 1, followed by a prolongation of the ÜLZ (HR 0.57; plimab2) and the decrease in the overall clinical trial. Women tend to benefit consistently less than men from CPI monotherapy [24].",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.6.2.2.1.1 PD-L1 ≥50 %",
        "start_page": 46,
        "end_page": 47,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "These observations require confirmation before they lead therapy decisions.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.6.2.2.1.1 PD-L1 ≥50 %",
        "start_page": 46,
        "end_page": 47,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "Immunochemotherapy is recommended if there are no contraindications against platinum-based chemotherapy. The combination of a CPI with platinum-based chemotherapy is also a possible alternative pat. with high PD-L1 expression and remission pressure due to stressful symptoms, high tumor load or rapid tumor growth. The type of immunochemotherapy is determined by histology and the degree of expression of PD-L1, each based on the approval studies and conditions.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.6.2.2.1.2 Suitable for platinum-based therapy",
        "start_page": 47,
        "end_page": 47,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In the case of the combination of praxin and praxin, the combination of praxin, praxin, praxin, praxin, praxin, taxin, praxin, praxin, praxin, praxin, praxin, prax, prax, prax, prax, pra, pra, In particular, the combination of anti-diagnosis and anti-diagnosis of the anti-diasis of the anti-diagnosis of the anti-thesis of the anti-diasis of the anti-diathesis of the anti-diasis of the anti-dia of the anti-thesis of the anti-diathesis of the anti-diathesis of the anti-diathesis of the anti-dia of the antithesis of the anti-dia of the anti-thesis of the antithesis of the anti-dia of the antithesis of the anti-thesis of the antithesis of the anti-dia of the anti In addition, the combination of the combination with the combination of the combination with the addition with the combination with In some randomised studies, the incidence of overdose was significantly increased compared to controls. Current options are given on dose regimens, respectively up to the occurrence of intolerant toxicity or progression: atezolizumab every 3 weeks following monotherapy for PD-L1 >50% or chemotherapy + cemiplimab for PD-L1 >1% durvalumab every 4 weeks following up to 4 cycles of chemotherapy + durvalu- mab / tremelimumab, as well as further administration of tremilimumab in cycle 6, nivolumab + ipilimumab following induction with immunocombination and chemotherapy; in the pivotal study, all cycles were given on dose regimens.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.6.2.2.1.2.1 Non-plate epithelial carcinoma",
        "start_page": 47,
        "end_page": 50,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In addition, in combination with the combination of the combination with In the case of high-risk patients, a significant delay in the median progression-free survival was observed from 4.8 to 6.4 months and for significant prolongation of overall survival time with an HR of 0.64 [97]. In the analysis of quality of life and patient report Outcome, a significant delay in time to worsening of physical function was observed in the pembrolizumab arm. Progression-free survival was not prolonged (HR 0.87; median 0.2 months) [67]. Monochemotherapy: Gemcitabine [100] Vinorelbin [105]",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.6.2.2.1.2.2 Panel epithelial carcinoma",
        "start_page": 50,
        "end_page": 51,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Docetaxel [107] Best Supportive Care: Supportive treatment is symptom-oriented.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "Pemetrexed in non-plate epithelial carcinoma [49]",
        "start_page": 51,
        "end_page": 51,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The anti-diagnosis of the anti-diagnosis. Afatinib resulted in a significant prolongation of survival time (hazard ratio 0.82; median 1.1 months) and PFÜ, not the remission rate. Diarrhoea and stomatitis in CTCAE grade ≥3/4 tra- ten more frequently with afatinib, exanthema (rash) on erlotinib. The FDA deleted this indication for erlotinib in 2016. In the case of oligoprogression under ongoing maintenance therapy with a CPI (pembrolizumab, atezolizumab, cemiplimab, nivolumab+ipilimumab), a continuation of the ICI and radiation of the oligoprogrediient metastasis can be offered. A potentially new option is the antibody conjugate datopotamab deruxtecan.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.6.2.2.2 Second-line therapy",
        "start_page": 51,
        "end_page": 52,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Datopo tamab is a significant anti-TROP2 antibody. In the study TROPION Lung 01 Üpotamab deruxtecan was not extended to docetaxel for the response rate of 0.74 vs.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.1.6.2.2.2 Second-line therapy",
        "start_page": 51,
        "end_page": 52,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "The majority of the patients who had been treated with the disease were treated with the disease. The majority of the patients who had had been treated with the disease were treated with the disease. The majority of patients who had been treated with the disease had been treated with the disease.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.1.1 Primary tumour",
        "start_page": 52,
        "end_page": 53,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The aim of lymph node removal in the context of tumor surgery is to improve the prognosis by precisely determining the tumor stage (N status) as the basis of the stadia-adapted postoperative therapy. Depending on the extent of lymph node removal, it is distinguished: Systematic lymph node dissection: In pre-defined compartments (interlobary, hilar and mediastinal) all lymph node stations and the lymph nodes present there are completely removed. This procedure has the highest sensitivity to dia- gnosis of an existing lymph node infestation. It is recommended as standard [117]. Systematic lymph node sampling: In this case, individual lymph nodes are removed from the pre-defined lymph node stations.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.1.2 Lymph nodes",
        "start_page": 53,
        "end_page": 53,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Punctual lymph node sampling: removal of single eye-catching lymph nodes. An increase in post-operative morbidity or letality associated with lymph node dissection is not documented. Also in PET - negative mediastinals are dependent on the tumor localization and size in 10-16 % tumor-fallen lymph nodes in a systemtektically detek.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.1.2 Lymph nodes",
        "start_page": 53,
        "end_page": 53,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "Radiotherapy is an effective therapy for non-small cell lung carcinoma. It is indi- trated with non-operable epidemiology in stages I and II, and in case of selective epidemiology in stage III. Options are: hyperfraction (CHART) conventionally fractionated with ≥60 Gy stereotactically In surgery Pat. is an irradiation indicated after incomplete resection. In the post-opera- tive situation after R0 resection in N0 or N1 status, it has an adverse influence on the prognosis and is not indicated. In higher N-stages, post-operative radiotherapy often led to an improvement of local control, but not of disease-free survival or overall survival, and can therefore no longer be recommended regularly in the case of overall epidemiology, but is recommended for frequency and frequency.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.2.1 Single radiotherapy",
        "start_page": 53,
        "end_page": 54,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The combination of radiotherapy with drug tumour therapy is more effective than radiotherapy alone and indicated in Pat. in stage III [20, 85, 103]. Effective medications and combinations for radiochemotherapy are: cisplatin / etoposid cisplatin / vinorelbin cisplatin monotherapy carboplatin monotherapy in elderly Pat. carboplatin / paclitaxel cisplatin / pemetrexed in non-plattene epithelium carcinoma, see also the currently valid approval information. The value of a supplement of system therapy by simultaneous administration of CPI is not confirmed, this combination is not recommended outside clinical studies. The recommendations for consolidating immunotherapy in stages IIIA multilevel (IIIA), IIIA and IIIB are defined in 3 3m 4 chapters 6. 4.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.2.2 Combined radiochemotherapy",
        "start_page": 54,
        "end_page": 54,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "and Chapter 6. 4. Recommended doses are grouped under pulmonary carcinoma therapy protocols.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.2.2 Combined radiochemotherapy",
        "start_page": 54,
        "end_page": 54,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "Systemic tumor therapy is used in non-small cell lung carcinoma in the primary neoadjuvant and adjuvant situations, in combination with radiotherapy and in the non-curative intended treatment situation, see Figures 4, 5, 6 and 7. For further information, please refer to the current approval status.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3 Drug therapy",
        "start_page": 54,
        "end_page": 54,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Cytostatic drugs are gonadotoxic. Pat. with incomplete family planning should be pointed out measures to maintain fertility, see Onkopedia Guideline - Maintenance of fertility.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.1 Cytostatics",
        "start_page": 54,
        "end_page": 54,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Carboplatin is a platinum derivative. It has a more favourable spectrum of side effects than cisplatin, but is slightly less effective at the emission rates. Survival times are comparable. Specific severe side effects are hematotoxicity (thrombocytopenia, anaemia, neutropenia), nausea and vomiting, neurotoxicity. The decision on the platinum component in a combination therapy should be based on the different toxicity profile of the two substances and on the existing comorbidities in individual cases.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.1.1 Carboplatin",
        "start_page": 55,
        "end_page": 55,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Platinum derivatives are among the most effective single substances. In combination with other cytostatic agents, cisplatin is part of the drug standard in primary (neoadj vuant), adjuvant and palliative therapy as well as in combination with radiation therapy. In palliative therapy, cisplatin in combination with taxanes, gemcitabine, vinorelbin or pemetrexed achieves remission rates of 15 – 30% and a mean PFÜ of 3 – 5 months. Specific severe adverse reactions (Grade 3/4) are nausea and vomiting, nephrotoxicity, polyneuropathy, ototoxicity, haematotoxicity, electrolyte shifts, cardiotoxicity and diarrhea. The decision of the platinum component (carboplatin or cisplatin) should be based on the different toxicity profile of the two substances and on the existing comorbidities in individual cases.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.1.2 Cisplatin",
        "start_page": 55,
        "end_page": 55,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Docetaxel belongs to the taxane group. Taxanes are effective combination partners of the plate in derivatives in the primary (neoadjvuants), adjuvant and palliative therapy as well as in combination with radiation therapy. However, they can also be used in other combinations, e.g. with gemcitabine, see lung cancer therapy protocols. For second-line monotherapy, docetaxel is more effective than vinorelbin or ifosfamid. In the ECOG study comparing four platinum-based combination therapies, the following severe side effects (CTCAE Grade 3/4) occurred in cisplatin/docetaxel: neutropenia (69%), febrile neutropenia (11%), anaemia (15%), thrombocytopenia (3%), vomiting (21%), diarrhoea (10%), nephroto-xicity (3%) and neuropathy (5%) and fatigue (16%). Other side effects are oedema, alopecia, onychodys and reactions.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.1.3 Docetaxel",
        "start_page": 55,
        "end_page": 55,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Gemcitabine is a pyrimidine analogue and belongs to the so-called third-generation cytostatics with taxanes, vinorelbin, irinotecan and pemetrexed. Gemcitabine is an effective combination partner of platinum derivatives in primary (neoadjvuant), adjuvant and palliative therapy. In palliative platinum-based combination therapy, it is equieffective to taxanes, but can also be used in non-platinum-based therapy, see lung carcinoma therapy protocols. In the ECOG study comparing four platinum-based combination therapies, the following severe adverse reactions (grade 3/4) occurred in cispla-tin/gemcitabine: neutropenia (63%), febrile neutropenia (4%), anaemia (28%), thrombocy topenia (50%), vomiting (35%), nephrotoxicity (9%), neuropathy (9%) and fatigue (17%).",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.1.4 Gemcitabine",
        "start_page": 55,
        "end_page": 55,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In the ECOG study comparing four platinum-based combination therapies, the following severe adverse reactions (grade 3/4) occurred in cisplatin/ paclitaxel: neutropenia (65%), febrile neutropenia (16%), anaemia (13%), thrombocytopenia (6%), vomiting (24%), diarrhoea (7%), nephrotoxicity (3%), neuropathy (5%) and fatigue (4%). Other adverse reactions were oedema, alopecia, onychodystrophy and allergic reactions. An alternative to the solvent-based paclitaxel (sodium-based, hypoglycaemic, hypoglycaemic, hypoglycaemic, hypoglycaemic, hypoglycaemic, hypoglycaemic.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.1.5 Paclitaxel / nabPaclitaxel",
        "start_page": 56,
        "end_page": 56,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Pemetrexed is an inhibitor of various folic acid-dependent enzymes. In Pat.'s first-line therapie with adenocarcinoma or with large cell carcinoma, it is a more effective combination partner of cisplatin than gemcitabine. TTF1 negativity is a negative predictive factor for pemetrexed [Frost 2020]. In these patients, a replacement by a gemcitabine, taxane, or vinorelbine-based regimen of therapy is to be discussed. In Pat. with adenocarcinoma, which was not progressive under a platinum-containing first-line therapy, alternating (switch maintenance) and continuous (continuous maintenance) maintenance therapy with pemetrexed resulted in a statistically significant prolongation of survival time. Severe adverse reactions (Grade 3/4) that occurred in the pivotal studies were: fatigue (5%), neutropenia (3-5%), anaemia (2-4%), infections (2 fetropia) and neutropia (2%).",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.1.6 Pemetrexed",
        "start_page": 56,
        "end_page": 56,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Vinorelbin is a semisynthetic derivative of the vinca alkaloid vinblastin. Vinca alkaloids are effective combination partners of platinum derivatives in primary (neoadjvuant), adjuvant and palliative therapy as well as in combination with radiation therapy. In palliative monotherapy it achieves remission rates of 10%, see drug-related tumor therapy protocols. Vinorelbin can be administered orally or intravenously. In the adjuvant chemotherapy studies it was one of the most frequently chosen combination partners of cispla-tin. In the LACE study on the effectiveness of adjuvant chemotherapy, the following severe adverse reactions (Grade 3/4) occurred in cisplatin/vinorelbin: neutropenia (80%), febrile neutropenia (9%), thrombocytopenia (3%), nausea/ vomiting (20%), constipation (4%), nephrotoxicity (1%) and neuropathy (3%).",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.1.7 Vinorelbin / Vinca alkaloids",
        "start_page": 56,
        "end_page": 56,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Atezolizumab is a monoclonal anti-PD-L1 antibody and belongs to the CPI class of substances. Atezolizumab is also approved in addition to the NSCLC in SCLC, hepatocellular carcinoma (HCC), triple negative breast cancer and in urothelial carcinoma. NSCLC uses it in curative and non-curative therapy as monotherapy and in combinations. Atezolizumab is administered as an intravenous infusion. Adverse reactions are substance class specific. In the course of an ICI-based therapy, immune-mediated side effects (irAE) may occur through autoimmune-mediated inflammation of different tissues or organs. For detection and management, we refer to current guidelines. After IRAE has subsided, ICI therapy is continued in certain situations, weighing the benefit as anti-tumour therapy against the risks of renewed, higher grade IRAE.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.2.1 Atezolizumab",
        "start_page": 57,
        "end_page": 57,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Durvalumab is a monoclonal anti-PD-L1 antibody and belongs to the CPI class of substances. Durvalumab is also approved in addition to the NSCLC in SCLC, biliary tumours and hepatocellular carcinoma (HCC). NSCLC uses it as monotherapie in localised stage III after definitive radiochemotherapy and in stage IV in combination with Tremelimumab and chemotherapy. Durvalumab is administered as an intravenous infusion. Adverse reactions are class-specific. In the course of an ICI-based therapy, ICI therapy may occur as immune-mediated adverse reactions (irAE) due to autoimmune-mediated inflammation of different tissues or organs. For detection and management, we refer to current guidelines. In certain situations, ICI therapy is continued in consideration of the benefit as anti-tumour therapy compared to the risks of renewed, higher-grade irAE.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.2.2 Durvalumab",
        "start_page": 57,
        "end_page": 57,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Ipilimumab is a monoclonal anti-CTLA-4 antibody and belongs to the class of substances of the CPI. Ipilimumab is approved in addition to the NSCLC also in the colorectal carcinoma, melanoma, mesothelioma, renal cell carcinoma and in the squamous cell carcinoma of the oesophagus. NSCLC uses it in combination with nivolumab and chemotherapy in non-curative therapy. Ipilimumab is administered as an intravenous infusion. Adverse reactions are substance-class specific. In the course of an ICI-based therapy, immune-mediated side effects (irAE) may occur through autoimmune-mediated inflammation of various tissues or organs. For detection and management, we refer to current guidelines [S3, Onco- pedia]. In certain situations, ICI therapy will continue in consideration of the benefit of antitumor therapy compared to the risks of renewed, higher grade IRAE.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.2.3 Ipilimumab",
        "start_page": 57,
        "end_page": 57,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Nivolumab is a monoclonal anti-PD-1 antibody and belongs to the CPI class of substances. Nivolumab is also approved in Hodgkin's lymphoma, colorectal carcinoma, mela-nom, renal cell carcinoma, squamous cell carcinoma of the head and neck region, squamous cell carcinoma of the oesophagus, pleuramesothelioma and urothelium. NSCLC uses it in curative and non-curative therapy as monotherapy, in combination with ipilimu- mab and in combination with chemotherapy. Nivolumab is administered as an intravenous infusion. Adverse reactions are substance-specific. In the course of an ICI-based therapy, immune-mediated adverse reactions (irAE) may occur through autoimmune-mediated inflammation of various tissues or organs. For detection and management, we refer to current guidelines.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.2.4 Nivolumab",
        "start_page": 57,
        "end_page": 58,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Pembrolizumab is a monoclonal anti-PD-1 antibody and belongs to the CPI class of substances. Pembrolizumab is also approved in biliary tumours, endometrial carcinoma, hodgkin lymphoma, colorectal carcinoma, triple negative breast cancer, melanoma, renal cell carcinoma, squamous cell carcinoma of the head and neck region, gastric carcinoma, oesophageal carcinoma, urothelial carcinoma and cervical carcinoma. NSCLC uses it in curative and non-curative therapy as monotherapy and in combinations. Pembrolizumab is used as an intravenous infusion. Adverse reactions are substance-specific. In the course of ICI-based therapy, immunomediated side effects (iraE) can be seen as autoimmune-mediated inflammation of different tissues or organs. For detection and management, we refer to the use of ICI-related agents in the course of treatment.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.2.5 Pembrolizumab",
        "start_page": 58,
        "end_page": 58,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Tislelizumab is a monoclonal anti-PD-1 antibody and belongs to the CPI class of substances. Tislelizumab is also used in gastric and oesophageal carcinoma in addition to the NSCLC. In the non-curative situation, it is used for first-line therapy in patients with non-plate epithelial NSCLC and PD-L1 expression ≥50% in combination with chemotherapy and in patients with plate epithelial NSCLC regardless of PD-L1 expression. Tislelizumab is also approved as monotherapy after prior platinum based therapy. Adverse reactions are substance class specific.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.2.6 Tislelizumab",
        "start_page": 58,
        "end_page": 58,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Tremelimumab is a monoclonal anti-CTLA-4 antibody and belongs to the CPI class of substances. Tremelimumab is also used in hepatocellular carcinoma (HCC) in addition to the NSCLC. NSCLC is used in advanced stages in combination with durvalumab and chemotherapy. Tremelimumab is administered as an intravenous infusion. Adverse reactions are class-specific. In the course of an ICI-based therapy, immune-mediated adverse reactions (irAE) may occur due to autoimmune-mediated inflammation of the tissues or organs. For detection and management, we refer to current guidelines. In certain situations, ICI therapy is continued as an antitumour therapy against the risks of renewed, higher IRAE.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.2.2.7 Tremelimumab",
        "start_page": 58,
        "end_page": 58,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Adagrasib is a selective inhibitor of KRAS G12C. It is approved for the treatment of Pat. with advanced NSCLC with KRAS G12C mutation and progress after at least one systemic therapy. Adagrasib is administered orally. Most common adverse reactions of all degrees of severity based on KRYSTAL-12 data are gastrointestinal with diarrhoea (53%), nausea (35%), hepatic with transaminases (30%) and renal with creatinine increase (20%). Also QTc time prolongations are described. Adagrasib is metabolised in the liver via cytochrome P450 and especially via CYP3A4. Concomitant treatment with CYP3A4 inducers and inhibitors should be avoided.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.3.1 Adagrasib",
        "start_page": 59,
        "end_page": 59,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Afatinib is an irreversible inhibitor of EGFR tyrosine kinases and belongs to the second generati- ons TKI in this indication. It is approved for the treatment of TKI-naivien Pat. with advanced NSCLC and activating EGFR mutations. Afatinib has also been approved for the treatment of rare EGFR mutations G719X, L861Q and S768I efficacy. Authorisation in the EU is not limited to specific mutations. In Switzerland, afatinib is also approved for the treatment of tumours with atypical mutations G719X, S768I and L861Q. In addition, afatinib is approved for the treatment of NSCLC-Pat. with plate epithelial histology and progression after platinum-based chemotherapy.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.3.2 Afatinib",
        "start_page": 59,
        "end_page": 59,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Adverse reactions of afatinib are class-specific. Adverse reactions in CTCAE Grade 3/4, which occur in the approval studies in more than 5% of the pat.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.3.2 Afatinib",
        "start_page": 59,
        "end_page": 59,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "Alectinib is an inhibitor of ALK and RET, it belongs to the second generation ALK inhibitors. It is approved for the treatment of Pat. with advanced, ALK positive NSCLC in the first line as well as in the second line after pre-treatment with crizotinib. In addition, the CHMP of the EMA has currently issued a recommendation for the approval of alectinib in the adjuvant therapie of the ALK positive NSCLC after complete resection and at high risk of recurrence. Alectinib is administered orally as monotherapy. Severe adverse reactions in the CTCAE grade 3-5 occurred in the pivotal study on first line therapy at 41% of patients. These include anaemia, myalgia, increased bilirubin, increased transaminases, increased CPK, weight gain, musculoskeletal pain and photosensitivity.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.3.3 Alectinib",
        "start_page": 59,
        "end_page": 59,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Amivantamab is a bispecific antibody against MET and EGFR. In NSCLC with EGFR mutation del19 / L858R it is approved in combination with TKI lazertinib for non-pre-traded Pat., and in combination with carboplatin / pemetrexed in previously treated Pat. As special adverse reactions of amivantamab, the increased rate of infusion reactions, skin reactions and venous thromboembolisms should be noted. In MARIPOSA, the rate of severe adverse events in CTCAE grade ≥3 with amivantamab + lazertinib was 72%, with amivantamab + chemotherapy. In 37% of patients in the amivantamab / lazertinib arm, thromboembolic events occurred, pulmonary embolism was 17%.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.3.4 Amivatanab",
        "start_page": 59,
        "end_page": 60,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "For the first 4 months of therapy, drug-related thrombosis prophylaxis with an oral DOAK or low-molecular heparin was recommended. Commonly, the majority of these reactions were documented in this class.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.3.4 Amivatanab",
        "start_page": 59,
        "end_page": 60,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "Brigatinib is a tyrosine kinase inhibitor with a broad spectrum of activity, including ALK and EGFR, It is a second-generation ALK inhibitor. Brigatinib is approved for the treatment of Pat. with advanced, ALK positive NSCLC in the first line as well as in the second line after pretherapy with crizotinib. Alectinib is administered orally as monotherapy. Severe side effects in CTCAE Grade 3/4 occurred in the pivotal study in 61-69% of patients receiving Briga-tinib. These included gastrointestinal adverse reactions with nausea and diarrhoea, arterial hypertension, elevated CK, increased amylase and lipase, increased transaminases, bradycardia, prolongation of QTc, fatigue, visual disturbances, exanthema and photosensibility.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.3.5 Brigatinib",
        "start_page": 60,
        "end_page": 60,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Pulmonary adverse reactions 3 and 4 occurred early in the treatment of the patient, especially in the treatment of 2.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.3.5 Brigatinib",
        "start_page": 60,
        "end_page": 60,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "Capmatinib is a MET inhibitor approved in the EU from the second line for Pat. with a MET Exon 14 skipping mutation. Capmatinib was taken from the German market by the pharmaceutical entrepreneur in September 2023.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.3.6 Cabmatinib",
        "start_page": 60,
        "end_page": 60,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Ceritinib is a selective ALK inhibitor and belongs to the second generation TKI in this indi cation. Ceritinib is approved for the treatment of Pat. with advanced, ALK positive NSCLC in the first line as well as in the second line after pre-therapy with crizotinib. Ceritinib is administered orally as monotherapy. Severe side effects of ceritinib from the first pivotal study are hepatotoxicity, gastrointestinal toxicity, prolongation of QT time and bradycardia. Other side effects include diarrhoea, nausea/ vomiting, fatigue, increased transaminases, abdominal pain and loss of appetite. The now approved, lower dose is burdened with less side effects.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.1.3.7 Ceritinib",
        "start_page": 60,
        "end_page": 60,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Crizotinib is an inhibitor of phosphorylation of tyrosine kinases such as ALK, MET and ROS1 and belongs to the first-generation TKI in this indication. Crizotinib is approved for the treatment of patients with advanced, ALK positive and ROS1 positive NSCLC. Further approvals in children and adolescents include recurrent/refractary ALK positive large cell lymphoma and inoperable, inflammatory myofibroblastic tumour. Adverse reactions in CTCAE Grade 3/4, which occur in more than 5% of patients treated with crizotinib, are transaminases increase (14-16 %), neutropenia (11-13 %) and pulmonary embolism (5%).",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.3.8 Crizotinib",
        "start_page": 60,
        "end_page": 61,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Characteristic side effects of crizotinib are visual disorders and taste changes.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.3.8 Crizotinib",
        "start_page": 60,
        "end_page": 61,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "Dabrafenib is a BRAF inhibitor. It inhibits the MAPK signal transmission pathway. Dabrafenib in combination with trametinib is approved for the treatment of advanced NSCLC with a BRAF V600 mutation. Dabrafenib is also approved for BRAF V600 mutated mela nom in addition to the NSCLC. Dabrafenib + trametinib are administered orally. Adverse reactions that occurred most frequently with dabrafenib+trametinib were fever (56%), nausea (51%), vomiting (41%), dry skin (39%), peripheral oedema (38%), diarrhoea (37%), appetite (33%) and cough (31%). Adverse reactions in CTCAE grade 3/4 were neutropenia (5%), hyponatriemia (7%) and anaemia (5%).",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.3.9 Dabrafenib",
        "start_page": 61,
        "end_page": 61,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "It is unclear whether the rate of secondary neoplasms, especially skin, is increased under the combination dabrafenib/trametinib in NSCLC.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.3.9 Dabrafenib",
        "start_page": 61,
        "end_page": 61,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "Dacomitinib is an irreversible second generation inhibitor of EGFR tyrosine kinases. Dacomitinib is approved for the first-line therapy of Pat. with advanced NSCLC and evidence of an acti- four-fold EGFR mutation. Severe adverse reactions in CTCAE grade 3/4 occurred in the pivotal study in 53% of patients receiving dacomitinib. Severe adverse reactions occurring in more than 5% of patients were acne (14%), diarrhoea (8%) and paronychie (7%). Diarrhea requires supportive measures, possibly dose reduction.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.3.10 Dacomitinib",
        "start_page": 61,
        "end_page": 61,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Entrectinib is an oral inhibitor of neurotrophic tyrosine receptor kinases (NTRK) and an inhibitor of ROS1. Entrectinib is approved for the first-line therapy of Pat. with ROS1 positive, advanced NSCLC. It is also approved in adults and in paediatric patients from 12 years of age with locally advanced or metastatic, solid tumours and evidence of neurotrophic tyrosine receptor kinase (NTRK) gene fusion if no satisfactory treatment options are available and if no NTRK inhibitor has been used. Entrectinib is used as monotherapy. Severe adverse events in CTCAE grade >3 occurred in the pivotal study at 68.5% of patients. The most common side effects were fatigue, dysgeusia, oedema with weight gain, confusion, diarrhoea, dysaesthesia, dyscetone, anaemia, neutropenia, congestive disease, and increased risk of heart disease.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.3.11 Entrectinib",
        "start_page": 61,
        "end_page": 61,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Erlotinib is an oral first-generation inhibitor of the tyrosine kinase activity of the EGF receptor (EGFR). It is approved for the first-line therapy of Pat. with locally advanced or metastatic NSCLC with activating EGFR mutations. Erlotinib is also approved for switching maintenance treatment in Pat. with locally advanced or metastatic NSCLC with activating EGFR mutations and unchanged disease status after platinum-based first-line chemotherapy. In addition, Erlotinib has an authorisation for Pat. with locally advanced or metastatic NSCLC, in which at least one previous chemotherapy has failed. Another authorisation is for metastatic pancreatic carcinoma in combination with gemcitabine. In NSCLC, erlo-tinib is used as oral monotherapy or in combination with ramucirumab.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.3.12 Erlotinib",
        "start_page": 61,
        "end_page": 62,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Other severe adverse reactions (Grade 3/4) that occurred in large randomised studies were diarrhoea (4%), anorexia (1-9 %) and fatigue (10 %).",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "Characteristic side effect is an acne-like rash. It occurs at 60% of the",
        "start_page": 62,
        "end_page": 62,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Gefitinib is an oral first-generation inhibitor of the tyrosine kinase activity of the EGF receptor (EGFR). It is approved for the treatment of Pat. with locally advanced or metastatic NSCLC with activating EGFR mutations. Gefitinib is used as oral monotherapy. Characteristic side effect is an acne-like rash (Rash). It occurs in 66% of patients, at a severity of 3/4 at 3%. Other severe adverse reactions (Grade 3/4), which occurred in large randomized studies, were diarrhoea (4%), anorexia (1-5%) and anaemia (2",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.3.13 Gefitinib",
        "start_page": 62,
        "end_page": 62,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Larotrectinib is an oral inhibitor of neurotrophic tyrosine receptor kinases (NTRK). Larot rectinib is used as a monotherapy for the treatment of adult and paediatric patients with solid tumours and evidence of neurotrophic tyrosine receptor kinase (NTRK) gene fusion. It is approved in locally advanced or metastatic disease for which satisfactory treatment options are not available. The safety of larotrectinib was recorded in all patients of the approval studies, 30% of patients were paediatric. Adverse reactions in Grade 3/4 occurred in 5% of patients. The most common adverse reactions were (in decreasing frequency): Fatigue (32%), increased ALT (31%), dizziness (30%), increased AST (29%), constipation (29%), nausea (26%), anaemia (24%) and vomiting (20%). Entrectinib is metabolised via cytochrome P450 and above CYP3A4.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.3.14 Larotrectinib",
        "start_page": 62,
        "end_page": 62,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The same inhibitor should be avoided with CYP3A.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.3.14 Larotrectinib",
        "start_page": 62,
        "end_page": 62,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "Lorlatinib is a third-generation inhibitor of Anaplastic Lymphoma Kinase, specifically designed to overcome the blood-brain barrier. Lorlatinib also inhibits ROS1. It is approved in Pat. with ALK+ NSCLC in first-line therapy and after prior therapy with alectinib, ceritinib or crizotinib, Lorlatinib is administered orally as monotherapy. The spectrum of adverse reactions differs from other inhibitors and includes hypercholesterolaemia (81%), hypertriglyceri-",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.3.15 Lorlatinib",
        "start_page": 62,
        "end_page": 62,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Cognitive and neuropsychiatric changes. Lorlatinib is a substrate of CYP3A4. Concomitant treatment with CYP3A4 inducers and inhibitors should be avoided.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "daemia (60%), oedema, weight gain (not water retention), peripheral neuropathy,",
        "start_page": 62,
        "end_page": 62,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Osimertinib is an oral EGFR tyrosine kinase inhibitor of the third generation. It is approved for adjuvant therapy with Pat. with NSCLC in stage IB-III when there is evidence of an EGFR mutation del19 or L858R in patients with locally advanced, inoperable NSCLC and evidence of an EGFR mutation del19 or L858R whose disease is not advanced during or after platinum-containing radiochemotherapy, for first-line therapy with Pat. with locally advanced or metastatic NSCLC with activating EGFR mutations, and with Pat. with locally advanced or metastatic NSCLC and evidence of an EGFR T790M mutation. Osimertinib is indicated in these indications orally as monotherapy.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.3.16 Osimertinib",
        "start_page": 63,
        "end_page": 63,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "New is the option of combination with chemotherapy in metastatic stage with new risk pat. Osimertinib- associated adverse reactions in CTCAE Grade 3/4 are observed in the approval studies for more than 13 % of the indication.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.3.16 Osimertinib",
        "start_page": 63,
        "end_page": 63,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "Pralsetinib is a selective RET inhibitor. Pralsetinib is used for the treatment of Pat. with Rearran-d-d-d-during-Transfaction (RET) fusion-positive advanced NSCLC not previously treated with a RET inhibitor. Pralsetinib is administered orally as monotherapy. Adverse reactions were mainly neutropenia (42% all grades, 20% in CTCAE grade >3), anaemia (38/13 %), high blood pressure (25/12 %). Other adverse reactions were 15% dysgeusia (grade 1.2), and dry mouth (15% grade 1/2). Febril neutropenia were not observed. It is currently unclear whether Pralsetinib will continue to be available on the German market.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.3.17 Pralsetinib",
        "start_page": 63,
        "end_page": 63,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Selpercatinib is a selective RET inhibitor. Selpercatinib is used for the treatment of Pat. with rear-ragged-during-transfaction (RET) fusion positive advanced NSCLC that require systemic therapy after platinum-based chemotherapy and/or treatment with immunotherapy. Selpercatinib also has an approval in advanced RET fusion positive thyroid carcinoma. It is administered orally as monotherapy. The most common side effects were arterial hypertension (14%), increase in transaminases (13%), hyponatria (6%) and lymphocytopenia (6%). QTc can be prolonged. In 30% of patients a dose reduction had to be performed.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.3.18 Sellercatinib",
        "start_page": 63,
        "end_page": 63,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Sotorasib is a selective KRAS G12C inhibitor. It is now approved for the treatment of Pat. with advanced NSCLC with KRAS G12C mutation and progress after at least one prior systemic therapy, and is withdrawn from the market in Switzerland. Sotorasib is administered orally. In CodeBreak 200, adverse events occurred in the CTCAE grade ≥3/4 at 33% of patients receiving Sotorasib vs 40% docetaxel. The most common severe adverse events with Sotorasib were diarrhoea (12%) and increase in transaminases (8%). 16.6% of patients in the sotorasib arm discontinued therapy due to side effects, in the docetaxel arm it was 15.9%. In vitro studies suggest that sotorasib is metabolised by cytochrome P450 (CYP) 2C8, CYP3A4 and CYP3A5 and is a substrate of Plypoprotein.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.3.19 Sotorasib",
        "start_page": 63,
        "end_page": 64,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Tepotinib is a MET inhibitor approved in the EU from the second line for Pat. with advanced NSCLC and evidence of MET Exon 14 skipping mutation requiring systemic therapy after platinum-based chemotherapy and/or immunotherapy. Tepotinib is administered orally as monotherapy. Peripheral oedema was the most common side effect, it occurred to 63%, Grades 1-2 56%, Grade 3 7%. Pat. with MET Exon 14 skipping mutations are often older than the median of NSCLC patients (median age in study 74 years) due to smoking status (40 to 50%) with more comorbidities.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.3.20 Tepotinib",
        "start_page": 64,
        "end_page": 64,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "See Chapter 6. 2. 3. 3. 9 and medicinal products trametinib.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.3.21 Trametinib",
        "start_page": 64,
        "end_page": 64,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Trastuzumab Deruxtecan is the conjugate of an anti-HER2 antibody and the topoisome-rase inhibitor SN38, the active metabolite of Irinotecan. Trastuzumab Deruxtecan is approved for the treatment of Pat. with advanced NSCLC, whose tumours have an active HER2 (ERBB2) mutation and which require systemic therapy after platinum-based chemotherapy with or without immunotherapy. Trastuzumab Deruxtecan is also approved for HER2+ and HER2low breast carcinoma as well as for Pat. with HER2+ adenocarcinoma of stomach or gastroesophageal transition. The most common severe UE were neutropenia and anaemia. Of particular interest in T-DXd are interstitial lung disease/pneumonitis and left ventricular dysfunction. In the pivotal study, 13 Pat. (12.9%) experienced interstitial pulmonary disease/pneumonitis, in the case of a patticular.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.3.22 Trastuzumab Deruxtecan (T-DXd)",
        "start_page": 64,
        "end_page": 64,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Bevacizumab is a monoclonal antiangiogenic antibody. It is approved for first-line therapy in patients with inope-rable advanced, metastatic or recurrent NSCLC in addition to placebo-containing chemotherapy, except for plate epithelial histology. Bevacizumab is administered intravenously and is used in combination therapies. Bevacizumab is also approved for colorectal carcinoma, breast and renal cell carcinoma. Severe adverse reactions in CTCAE Grade 3/4 were: haemorrhage (4%), hypertension (5–9%), asthenia (15–17%), fatigue (5%), proteinuria (1-4 %) and neutropenia in combination with chemotherapy. Due to the increased risk of postoperative bleeding complications, a time interval of several weeks after the last bevacizumab administration should be considered in elective surgery.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.4.1 Bevacizumab",
        "start_page": 64,
        "end_page": 65,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Nintedanib is an oral VEGFR and FGFR inhibitor. It is approved in oncology for second-line therapy in combination with docetaxel in patients with advanced or metastatic adenocarcinoma of the lungs. Adverse reactions in CTCAE Grade 3/4, which occurred in more than 5% of patients in combination with nintedanib, were diarrhoea (6.6%) and reversible elevations in transaminases (7.8%).",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.4.2 Nintedanib",
        "start_page": 65,
        "end_page": 65,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Ramucirumab is a human IgG1 antibody that is specific and with high affinity to the extracellular domain of the vascular endothelial growth factor receptor-2 (VEGFR2) bin- det. Ramucirumab is approved for the treatment of Pat. with locally advanced or metastatic NSCLC in progress during or after platinum-containing chemotherapy, regardless of histology and regardless of defined genetic markers. In combination with erlotinib, it is also approved in the first-line therapy of Pat. with advanced NSCLC and activating EGFR mutations. In addition, ramucirumab is approved in the combination of docetaxel + ramucirumab and in the adenocarcinoma of the stomach and the gastro-oesohageal transition. Adverse reactions in CTCAE Grade 3/4, which occurred in more than 5% of the pat.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.4.3 Ramucirumab",
        "start_page": 65,
        "end_page": 65,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "in the combination of docetaxel + ramucirumab and more frequently than in the control arm (aftropia, neutropia, neutropia, neutropia, neutropia)49.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.2.3.4.3 Ramucirumab",
        "start_page": 65,
        "end_page": 65,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "Endoluminal tumour growth or external compression can lead to bleeding, dyspnoea and/or retention symptoms in the trachea and central bronchies. Depending on the findings, tumor-bearing methods such as Nd-YAG lasers, argon beamer or cryothera pie, endoluminal small space radiation or prosthetic methods (endoluminal stents) are suitable for symptom relief. Stentimplantation can be combined with other physical methods such as endoscopic laser therapy or endoluminal brachytherapy. The aim is to extend the time to symptom recurrence. Results of randomized studies to compare the local therapy procedures are not available.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.3.1 Bronchus and tracheal stenosis",
        "start_page": 65,
        "end_page": 65,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Prerequisites for a local therapy are: symptomatic, malignant effusion and expansional lung and non-response to systemic drug therapy or contraindications against systemic drug therapy. Based on a meta-analysis of 36 randomized studies with a total of 1499 patients, thoracoscopic talc pleurodese has established itself as a standard [127]. More recent studies show that other concepts such as talc application via a catheter or the long-term insertion of tunneled pleuradrainage (indwelling pleural catheter) can achieve comparable results in symptom relief. Results of large randomized studies for establishing a new standard are pending.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.3.2 Malignant pleural effusion",
        "start_page": 65,
        "end_page": 66,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "For the treatment of pat. with bone metastases local and systemic measures are available. In case of pain symptoms or risk of fracture, radiation is the therapy of choice. It can be hypofractionally performed under continuous system therapy. An additional option is the surgical care for pathological fractures, unstable vertebral fractures or as relief in case of spinal compression. Systemic measures are the causal therapy and the administration of bone modifying substances (bisphosphonates, RANKL antibodies). Bone modifying substances can reduce the risk of skeletal complications in case of ossaric metastasis of solid tumours.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.3.3 Bone metastases",
        "start_page": 66,
        "end_page": 66,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In the subgroup analysis of a multi-centre study for the comparison of zoledronate and deno-sumab in solid tumours, Pat. with NSCLC under denosumab showed no significant difference in skeletal-related events, but a significantly longer overle-ben-time. Bisphosphonates are additionally indicated in hypercalcaemia.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.3.3 Bone metastases",
        "start_page": 66,
        "end_page": 66,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "The first measure of symptomatic metastasis is the administration of steroids to reduce perifocal oedema. In isolated, resectable brain metastases, local chirurgic therapy or targeted local radiation (gamma-knife, cyber-knife, stereotactic radiation) is recommended. In patients with solitary brain metastases, a curative therapy approach in combination with an optimal local therapy of the lung tumor exists, see Figure 4 and Chapter 6. 6. 1. In patients with small and asymptomatic brain metastases, abnormal behaviour with MRI controls under system therapy is an alternative to primary local therapy [113]. In particular, some of the molecularly targeted medications have a high efficacy in the CNS.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.3.4 Brain metastases",
        "start_page": 66,
        "end_page": 66,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Isolated liver metastases are rare in NSCLC-Pat. Therefore, systemic therapy is in the foreground. The benefit of locoregional therapy of liver metastases has not been established in lung-carcinoma-Pat.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.3.5 Isolated liver metastases",
        "start_page": 66,
        "end_page": 66,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Pat. with isolated adrenal metastases are a distinct group. With resection of the adrenal metastasis as well as optimal local therapy of the primary tumor there is a curative approach, see Figure 4 and Chapter 6. 1. 6. 1. The benefit of locoregional therapy of adrenal metastases is shown in Pat. in retrospective analyses, results are not available.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.3.6 Isolated adrenal metastases",
        "start_page": 66,
        "end_page": 67,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "During the course of the therapy, the incidence of HlV and the incidence of HlV, the incidence of Hl and the incidence of HlV, the incidence of HlV and the incidence of HlV, the incidence of Hl, the incidence of Hl and the incidence of Hl, the incidence of HlV, the incidence of Hl, the incidence of HlV, the incidence of Hl, the incidence of",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "6.3.7 HIV-associated lung carcinomas",
        "start_page": 67,
        "end_page": 67,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Surgery, radiotherapy, drug tumour therapy and comorbidity can lead to treatment-related disorders of different degrees of severity in patients with non-small cell lung cancer. They can be alleviated by targeted rehabilitation measures in the somatic and psychosocial areas. Pat. should be informed about the possibilities of outpatient and inpatient rehabilitation measures as well as other claims arising from the social law at an early stage. Regarding the rehabilitation clinic, the wishes of Pat. should be taken into account (§9 SGB IX). Nevertheless, a recommendation for a clinic with an oncological focus should be given in order to ensure an optimal rehabilitation success.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "7 Rehabilitation",
        "start_page": 67,
        "end_page": 67,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The aim of the follow-up care is the early diagnosis of a recurrence with the aim of prolonging the survival time / increasing the chance of healing, the detection of side effects of therapy and precaution. In patients with lung cancer, the value of an intensive, structured follow-up care with respect to an extension of the survival time is not assured. After curative therapy, the goal of the follow-up care is also the early diagnosis of a second tumor. In patients with recidiv or a second carcinoma, there is a curative potential. In these patients, the follow-up care interval can be reduced to 6-8 weeks [117]. Recommendations for conventional, structured follow-up after therapy in curative intention are summarised in Table 12.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "8.1 Curative therapy",
        "start_page": 67,
        "end_page": 68,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Table 12: Structured follow-up after curative therapy Examination Months Anamnesis, X X X X",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "8.1 Curative therapy",
        "start_page": 67,
        "end_page": 68,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "Lung function X X (X) (X) (X) Legend: * after radiotherapy; Pat. after radiotherapy alone or after radiochemotherapy should continue the examination of lung function until the end of the risk of pneumonitis [121]. In Pat. with an individually high risk of developing cerebral metastasis (e.g. large cell carcinomas, undifferentiated adenocarcinomas, small cell carcinomas or mixed tumors, rare lung tumour histologies) one should consider planning examinations at realistic intervals (6-9 months), but only in the first three years after local therapy, MRI-shafts with the follow-up concept.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "CT Thorax X* X* X X* X X X",
        "start_page": 68,
        "end_page": 68,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In Pat.'s palliative situation, after medical first-line therapy, there is the possibility of early initiation of second-line therapy in disease prevention. In the expert consensus, the S3 guideline recommends the reduction of the three-month to shorter, 6-8-week intervals [117]. Data from prospective studies on the optimal follow-up interval when using the current therapy options are not yet available. Promising, new options for Pat. in the palliative situation are the personalized monitoring of the patient and the disease progression by means of web-based instruments. In a French study, Pat. were randomized in advanced stages without disease progression between a weekly, web-based self-assessment and a standardized 3- and 6-month CT control.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "8.2 Non-curative intended therapy",
        "start_page": 68,
        "end_page": 68,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Pat. in the experimental arm had a significantly longer, median survival (HR 0.32; median 7 months) [28]. Current data from the USA support these results. The patient's satisfaction of video-received patients was not advanced at the time of the patient's consultation.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "8.2 Non-curative intended therapy",
        "start_page": 68,
        "end_page": 68,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "Can 4. Ant Non Moa 5. Ard Firs Met 6. Are Afte j.jth 7. Ata Lun plat 3 tr DOI 8. Aup rad 9. Bec Res DOI 10. Ber BJN 11. Blu nat ulat mo 12. Bra da Sta JCO 13. Bro Wh tase jam 14. Bru apy 15. Bun arte kra 16. Cad tion 17. Cam Adv ncer (NSCLC) with PD-L1 score ≥ 50%: FDA pooled analysis. ASCO Annual Meeting Lung carcinoma, non-small cell (NSCLC) – drug-related tumor therapy",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "9 Literature",
        "start_page": 69,
        "end_page": 79,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Lung carcinoma - Study results (randomised phase II studies, phase III studies, metaanalysis)",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "12 Study results",
        "start_page": 79,
        "end_page": 79,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Lung carcinomas - Authorisation status of medicinal products",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "13 Authorisation status",
        "start_page": 79,
        "end_page": 79,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Occupational Exposure 15 Addresses PD Dr. med. Gudrun A LKH-Univ. Klinikum Graz Univ. Klinik für Innere Me Clinical Department for O Auenbruggerplatz 15 A-8036 Graz gudrun.absenger@medu Univ.-Prof. Dr. med. An Uniklinikum Münster Medical Department A Hematology, Oncology, Albert-Schweitzer-Campu 48149 Münster annalen.bleckmann@ukm PD Dr. med. Wilfried E Universitätsklinikum Esse Westdeutsches Tumorzen Innere Klinik und Poliklini Hufelandstr. 55 45147 Essen Wilfried.Eberhardt@uk-e PD Dr.med. Martin Eic Surgical Department Thoraxklinik Universitätsklinikum Heid Röntgenstr. 1 69126 Heidelberg martin.eichhorn@med.un.un.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "14 Links",
        "start_page": 79,
        "end_page": 80,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Charité Universitätsmed Klinik für Infectiologie un Augustenburger Platz 1 13353 Berlin nikolaj.frost@charite.de",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "PD Dr. Nikolay Frost",
        "start_page": 80,
        "end_page": 80,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Kantonsspital St. Gallen Department Internal Med Department Oncology/H CH-9007 St. Gallen martin.frueh@kssg.ch PD Dr. med. Oliver Gau Lucerne Cantonal Hospital Medical Oncology CH-6000 Luzern oliver.gautschi@luks.ch de Abs ediz Onk unig nn, Pn us mu Ebe en ntr ik esse chh del ni-h dizi nd dizi Häm uts er sen zin kolo gra nale neu uen erh rum en. hor lbe he in B Int in mat sch r A nge n ogi az. en um nst har m .de rn erg eide Be ten tol hi Au er ie.at n B mol ter. rd e g elb erlin nsiv log ut Blec log .de dt ber n gin gin gin grin grin grin glin glin glin glin glin gin gin gin g",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "Dr. med. Martin Früh",
        "start_page": 80,
        "end_page": 81,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Department of Internal Medicine St. Elisabeth Hospital Biedermannstraße 84 04277 Leipzig sylvia.guetz@ek-leipzig.de Prim. Dr. Wo Wilhelminenspital Wien 1. Medical Department Center for Oncology and Montleartstr. 37 A-1160 Wien wolfgang.hilbe@wienkav.a Prof. Dr. med. Hans Ho Klinikum rechts der Isar der Technische Universit Section für Thoraxchirri Ismaninger Str. 22 81675 München thoraxschirgie@mri.tum. Prof. Dr. med. Rudolf M Klinikum der Universität Ziemssenstr. 1 80336 München huber@med.uni-muenche Dr. med. Klaus Kraywin Center for Cancer Register Robert Koch-Institut General-Pape-Straße 62-6 12101 Berlin k.kraywinkel@rki.de Prof. Dr.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "Dr. Sylvia Gütz",
        "start_page": 81,
        "end_page": 82,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "med. Dr. rer. Dr versit nik für matol gstett 106 Fr nelius of. Dr b. Ge mpus d. Klin guste 344 B nhard r. me tätsk utsch r Stra dstr. 5 Essen ph.Poe r. me Clinic gische damm Großh @lung r. me os Fac le On Koch-A Münch uth@ d. Ma tätskische Häm r-Ster Frankf an@m d. Jan gie Se Berlin l@onk r. me tätsk r Inne ologie, ter St reibu s.wal r. me esund Virch nik menburg Berlin d.woe ed. Chr klinikum hes Tum ahlenth ettgen@ ed. Mar Grossh er Schw",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "Dr. Sylvia Gütz",
        "start_page": 81,
        "end_page": 82,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "It is not possible to find a way of dealing with this problem, but it is not possible to find a way of dealing with this problem. It is not possible to find a way of dealing with this problem, but it is possible to find a way of dealing with this problem.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "m 80",
        "start_page": 82,
        "end_page": 83,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading none",
        "start_page": 1,
        "end_page": 1,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\nCause of SymptomRow 2:\nlocally tumor-related-Hust Dyspnoea chest pain Haemoptysen blood-tungated sputum in coughing upper influx (Vena-cava-superior syndrome) Dysphagia Stridor hoarseness (voice band paresis in infiltration of N. recurrens) Poor arm (infiltration of Plexus brachialis) Horner Syndrome (infiltration of Ganglion stellatum)Row 3:\nmetastasis-related-tired symptoms, e.g. bone or headache dizziness, headache, neurologic breakdowns, confusion, seizures lymph node swelling (supraclavicular) IkterusRow 4:\ngeneral-weight loss weakness fever night sweat paraneoplastic syndromes* autoimmune syndrome (collagenosis) endocrinous including clotting cutane, e. g.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "Table under heading 5.2.1 Initial diagnosis",
        "start_page": 13,
        "end_page": 13,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "zmatomyitis zetabolitis paraneoplastic syndrome.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "Table under heading 5.2.1 Initial diagnosis",
        "start_page": 13,
        "end_page": 13,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "Row 1:\nCause-SymptomRow 2:\nlocally tumor-related-Housing Dyspnoea chest pain Haemoptysen blood-tungated sputum in coughing upper influx (Vena-cava-superior syndrome) Dysphagia stridor hoarseness (voice band paresis in infiltration of N. recurrens) Poor arm (infiltration of Plexus brachialis) Horner syndrome (infiltration of Ganglion stellatum)Row 3:\nmetastasis-related-tired pain, e.g. bone or headache dizziness, headache, neurologic outages, confusion, seizures lymph node swelling (supraclavicular) IkterusRow 4:\ngeneral-weight loss weakness fever night sweat paraneoplastic syndromes* autoimmune (collagenosis) endocrine disease including coagulation cutane, e. g.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "Table under heading 5.2.1 Initial diagnosis (column 1)",
        "start_page": 13,
        "end_page": 13,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "zmatositis zetabolitis paraneoplastic syndrome.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "Table under heading 5.2.1 Initial diagnosis (column 1)",
        "start_page": 13,
        "end_page": 13,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "Row 1:\n.Row 2:\n.Row 3:\n.Row 4:\n. om) .",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "Table under heading 5.2.1 Initial diagnosis (column 2)",
        "start_page": 13,
        "end_page": 13,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\n.Row 2:\n.Row 3:\n.Row 4:\n.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "Table under heading 5.2.1 Initial diagnosis (column 3)",
        "start_page": 13,
        "end_page": 13,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\nInvestigation-RecommendationRow 2:\nLaboratory-Blood image, electrolytes, renal parameters, liver parameters, LDH, coagulationRow 3:\nCT1 Thorax / upper belly with contrast agent, or FDG-PET-CT2-Method of first choiceRow 4:\nMRT3 Thorax / upper belly with contrast agent-Alternative to CT1, if CT is not feasibleRow 5:\nBronchoscopy with biopsy4-In case of imaging suspicion and accessible space requirementRow 6:\nTransthoracic biopsyIn case of imaging suspicion and peripheral orbit, without the possibility of endoscopic securing of dia- gnosis",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading investigation recommendation",
        "start_page": 14,
        "end_page": 14,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "HG2 TG2 TG2 TG2 TG2 TG2 TG3 TG3 TG3 TG3 TG3 TG4 TG4 TG4 TG4 T4 T4 TG4 TG4 TG4",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading en [136],",
        "start_page": 15,
        "end_page": 15,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The following are some of the following: BAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-CAT-C",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "Table under heading en [136], (column 1)",
        "start_page": 15,
        "end_page": 15,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\nndoscopic investigationRow 6:\nastasenRow 7:\n Row 8:\n Row 9:\n Row 10:\nert-Row 11:\n Row 12:\n0M",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "Table under heading en [136], (column 2)",
        "start_page": 15,
        "end_page": 15,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\nRow:Row 6:\n Row 7:\n Row 8:\n Row 9:\n Row 10:\n Row 11:\n Row 12:\nRow",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "Table under heading en [136], (column 3)",
        "start_page": 15,
        "end_page": 15,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The following items are added in the following order:",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading en [136], (from previous page)",
        "start_page": 16,
        "end_page": 16,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\nCategorizationRow 2:\nT (Tumor:Row 3:\nN (Lymp:Row 4:\nM (Meta:",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading en [136], (from previous page, column 1)",
        "start_page": 16,
        "end_page": 16,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\nrie'Row 2:\nr)'Row 3:\nphknote'Row 4:\nastase)'",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading en [136], (from previous page, column 2)",
        "start_page": 16,
        "end_page": 16,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\n. . . .",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading en [136], (from previous page, column 3)",
        "start_page": 16,
        "end_page": 16,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\n. . . . .",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading en [136], (from previous page, column 4)",
        "start_page": 16,
        "end_page": 16,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The following are the following examples of the following:",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading en [136], (from previous page, column 5)",
        "start_page": 16,
        "end_page": 16,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\nM1 - M1 - M0 - M0 - T3 - T4 - N3 - N2 - N4 - N0 - N1 - N0 - N0 - N0 - M0 - M0 - M0 - M",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading en [136], (from previous page)",
        "start_page": 17,
        "end_page": 17,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\nStadium,Row 2:\n0,Row 3:\nIA1,Row 4:\nIA2,Row 5:\nIA3,Row 6:\nIB,Row 7:\nIIA,Row 8:\nIIB,Row 9:\nIIIA,Row 10:\nIIIB,Row 11:\nIIIC,Row 12:\nIVA,Row 13:\nIVB, Row",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading en [136], (from previous page, column 1)",
        "start_page": 17,
        "end_page": 17,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\nprimary tumorRow 2:\ntissowRow 3:\nieT1a(mi) T1a\"Row 4:\nieT1b\"Row 5:\nieT1c\"Row 6:\nieT2a\"Row 7:\nieT2b\"Row 8:\nieT1a\"-c T2a\" T2b T3\"Row 9:\nieT1a\"-c T2a\" T3 T4\"Row 10:\nieT1a\"-b T2a\" T3\"Row 11:\nieT3 T4\"Row 12:\nie\" each T\"Row 13:\nie\" each T\"Row 13:\nie\"",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading en [136], (from previous page, column 2)",
        "start_page": 17,
        "end_page": 17,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\n. . . .",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading en [136], (from previous page, column 3)",
        "start_page": 17,
        "end_page": 17,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\n-",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading en [136], (from previous page, column 4)",
        "start_page": 17,
        "end_page": 17,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\n-",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading en [136], (from previous page, column 7)",
        "start_page": 17,
        "end_page": 17,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\nMetastRow 2:\n Row 3:\n Row 4:\n Row 5:\n Row 6:\n Row 7:\n Row 8:\n Row 9:\n Row 10:\n Row 11:\n Row 12:\n Row 13:\nRow",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading en [136], (from previous page, column 8)",
        "start_page": 17,
        "end_page": 17,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\n Row 6:\n Row 7:\n Row 8:\n Row 9:\n Row 10:\n Row 11:\n Row 12:\n Row 13:\nRow",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading en [136], (from previous page, column 9)",
        "start_page": 17,
        "end_page": 17,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\n.Row 2:\n.Row 3:\n.Row 4:\n.Row 5:\n.Row 6:\n.Row 7:\n.Row 8:\n.Row 9:\n.Row 10:\n.Row 11:\n.Row 12:\n.Row 13:\n.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading en [136], (from previous page, column 10)",
        "start_page": 17,
        "end_page": 17,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "It is important to note that it is important to note that the information provided in this document.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading N2*",
        "start_page": 18,
        "end_page": 18,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\nKatego-Row 2:\nT (Tumo-Row 3:\nN (Lymp-Row 4:\nM)",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading N2* (column 1)",
        "start_page": 18,
        "end_page": 18,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\norie-row 2: or)-row 3: phknote-row 4: astase)-",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading N2* (column 2)",
        "start_page": 18,
        "end_page": 18,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading N2* (column 3)",
        "start_page": 18,
        "end_page": 18,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\n. . . . .",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading N2* (column 4)",
        "start_page": 18,
        "end_page": 18,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "4 / 4 / 4 /",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading N2* (column 5)",
        "start_page": 18,
        "end_page": 18,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\n Row 2:\nSingular LK metastasis in ipsilateral mediastinal and / or subcarinal lymph nodesRow 3:\nMultiple N2 LK metastases (ipsilateral mediastinal and / or subcarinal",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading N2* (column 5)",
        "start_page": 18,
        "end_page": 18,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In: IIADET2T2B2B2B0M0Row 8:\nIIB*T1a-c.c.N0M0Row 7:\nIIAET2b.N0M0Row 8:\nIIAADET2b.N0M0Row 7:\nIIAAET2b.N0M0Row 7:\nIIAAET2b.N00M0Row 8:\nIIB*T1aa-c.c.N00M0Row 9:\nIIB*T1a-c.c.N0M0Row 9:\nIIB*T1a-c.N0M0Row 9:\nIIB*T1a-c.N0 13: IIIA***T1a-c. IIIA**T1a-c.0T1a-c.2b.0Row 10:\nIIT2a.0M0Row10 11: IITT2b2b2b2b2b2b2Tl2T222T22: 12: 12: 12: 12: Il11M0T2M0l0lRlRlshshshshshshshshshshshshshshshshn 12 12 12 12 12 mouth mouth mouth mouth mouth1n 12 12 12:lshshshshshshshshshshdododododododododododododododododododododododododododododododododododododododododododododododododododododododododododododododododododododododododododododododododododododododododododododododododododododododododododododododododododododododododododododododododododododododododododododo",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading N2* (from previous page)",
        "start_page": 19,
        "end_page": 19,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\nStadium,Row 2:\n0,Row 3:\nIA1,Row 4:\nIA2,Row 5:\nIA3,Row 6:\nIB,Row 7:\nIIA,Row 8:\nIIB,Row 9:\nIIIA,Row 10:\nIIIB,Row 11:\nIIIC,Row 12:\nIVA,Row 13:\nIVB,Row 13:\nIVB",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading N2* (from previous page, column 1)",
        "start_page": 19,
        "end_page": 19,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\n.Row 2:\n.Row 3:\n.Row 4:\n.Row 5:\n.Row 6:\n.Row 7:\n.Row 8:\n.Row 9:\n.Row 10:\n.Row 11:\n.Row 12:\n.Row 13:\n.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading N2* (from previous page, column 2)",
        "start_page": 19,
        "end_page": 19,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In addition, there is a to to to",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading N2* (from previous page, column 3)",
        "start_page": 19,
        "end_page": 19,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\n. . . .",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading N2* (from previous page, column 4)",
        "start_page": 19,
        "end_page": 19,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\nRow:Row 1:\nRow: Row, Row,",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading N2* (from previous page, column 5)",
        "start_page": 19,
        "end_page": 19,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\n-",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading N2* (from previous page, column 6)",
        "start_page": 19,
        "end_page": 19,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading N2* (from previous page, column 6)",
        "start_page": 19,
        "end_page": 19,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\n. . . .",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading N2* (from previous page, column 7)",
        "start_page": 19,
        "end_page": 19,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\n. . . . .",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading N2* (from previous page, column 9)",
        "start_page": 19,
        "end_page": 19,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\n. . . . .",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading N2* (from previous page, column 10)",
        "start_page": 19,
        "end_page": 19,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\n. . . .",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading N2* (from previous page, column 11)",
        "start_page": 19,
        "end_page": 19,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\n.Row 2:\n.Row 3:\n.Row 4:\n.Row 5:\n.Row 6:\n.Row 7:\n.Row 8:\n.Row 9:\n.Row 10:\n.Row 11:\n.Row 12:\n.Row 13:\n.Row 14:\n.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading N2* (from previous page, column 12)",
        "start_page": 19,
        "end_page": 19,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\nStage--DescriptionRow 2:\nIIIA1--identical lymph node metastases in one or more lymph node stations after postoperative treatment in the preparationRow 3:\nIIIA2--intraoperative detection of lymph node metastases in a mediastinal lymph node station (intraoperatially fast-section) and if necessary termination of the procedure without resectionRow 4:\nIIIA3*--preoperative detection of lymph node metastases in one or more lymph node stations (PET, medi- astinoscopy, biopsy), potentially resectableRow 5:\nIIIA4---enhanced (bulky) or fixed N2 metastases or metastases in several lymph node stations (mediasti- nal lymph nodes > 2 – 3 cm) with extracapsular infiltration; not resectable",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading  Large cell carcinoma",
        "start_page": 20,
        "end_page": 20,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\nClassification-Differentization-Characterization-CriteriaRow 2:\nPlate-Epithel Carcinoma-Verhornend-Row 3:\nNon-horned (p40+, TTF1-)--(p40+, TTF1-)Row 4:\nBasaloid-P40+/TTF1-Row 5:\nAdenocarcinoma-Preinvasive--<3cm with <5mm InvasionRow 6:\nMinimally invasive--Row 7:\nInvasive G1 Lepidic G2 Azinary, Papillar G3 Micropapillary, Solid-",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading  Large cell carcinoma",
        "start_page": 20,
        "end_page": 20,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\nInvestigation-NoteRow 2:\nSpirometry: FEV11, TLCO2-Methods of the first choiceRow 3:\nFull-body plethysmography-Row 4:\nArterial blood gases at restRow 5:\nSpiroergometry-Pat. with restriction of FEV1 and / or diffusion capacity (TLCO), or other limiting cardiovascular risks or concomitant diseases",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading investigation Note",
        "start_page": 22,
        "end_page": 22,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\nRisk-based parameterRow 2:\nhighly unstable coronary heart disease recent myocardial infarction with evidence of relevant risk of ischemia based on clinical symptoms or non-invasive examinations unstable or severe angina pectoris (grade 3 or 4) decompensated heart failure significant arrhythmias AV Block II or III. Grade symptomatic ventricular arrhythmias in heart failure supraventricular arrhythmias with non-controlled heart rate severe heart valve diseaseRow 3:\nmoderate arrhythmias angina pectoris (grade 1 or 2) preceding myocardial infarction based on anamnesis or pathological Q zacken compensated heart failure or Z.",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "Table under heading 6.1 Therapeutic structure",
        "start_page": 23,
        "end_page": 23,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "decompensated heart failure diabetes mellitusRow 4:\nlow-advanced age (>70 years).",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "Table under heading 6.1 Therapeutic structure",
        "start_page": 23,
        "end_page": 23,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "Row 1:\n-",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading Figure 6: Algorithm for molecular stratified therapy in advanced stages",
        "start_page": 35,
        "end_page": 35,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\nInvestigations: Months: 36,612,18,24,36,48,60Row 2:\nHistory, physical examination: X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,X,",
      "metadata": {
        "doc_id": "lungenkarzinom-nicht-kleinzellig-nsclc",
        "heading": "table under heading 9 Literature",
        "start_page": 68,
        "end_page": 68,
        "created_date": "unknown_year",
        "country": "AT",
        "source_type": "clinical_guideline",
        "original_file_path": "nsclc_kras_g12c 2/clinical guidelines/AT/lungenkarzinom-nicht-kleinzellig-nsclc_cleaned.json",
        "split_index": 0
      }
    }
  ]
}